PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

The Digital International Liver Congress™ 2020

27-29 August 2020

N. Poster

Poster title

Applicant name

Status


THU-001	Adipose tissue insulin resistance and inflammation, but not reduced hepatic fat oxidation, are associated to active NASH and severe fibrosis	Amalia Gastaldelli	Received

SAT-001	Lipoprotein lipase deletion induces a proinflammatory phenoytpe in liver-infiltrating monocytes during non-alcoholic steatohepatits	Anja Koop	Received

FRI-001	The development of the naf3 score to accurately predict the presence of active NASH with advanced fibrosis	Naim Alkhouri	Received

LBP-001	Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)	Carrie Bray	Received

SAT-002	A translational mouse model for NASH and advanced fibrosis in association with atherosclerosis	Anita van den Hoek	Received

THU-002	Natural history and prognostic factors of compensated cirrhosis secondary to non-alcoholic steatohepatitis in Catalonia	Octavi Bassegoda	Received

LBP-003	HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial	Manal Abdelmalek	Received

SAT-003	Aberrant hepatic protein tyrosine phosphatase receptor type delta expression is a driver of metabolic liver disease	Armando Andres Roca Suarez	Received

FRI-003	Machine learning models identify novel histologic features predictive of clinical disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis	Vicki Mountain	Received

THU-003	Non-alcoholic fatty liver disease fibrosis score predicts cardiovascular mortality in post percutaneous coronary intervention patients: 5-year results from an observational registry	Dongyoung Lee	Received

LBP-004	Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400mg daily added to a nucleoside in HBV EAg negative patients	Kosh Agarwal	Received

THU-004	The association between liver fibrosis and cognitive impairment in type 2 diabetes: a cross-sectional sub-study of the south London diabetes cohort	Calum Moulton	Received

FRI-004	Serum proteomics identifies biomarkers of fibrotic severity in NASH patients	Christina Ebert	Received

SAT-004	LncRNA-H19 as a marker of liver progression from steatosis to hepatocellular carcinoma	Ángela Rojas	Received

SAT-005	The lipid composition of the liver: assessing differences in obese patients with and without non-alcoholic steatohepatitis	Anna Hernández-Aguilera	Received

FRI-005	Performance of non-invasive fibrosis tests among non-alcoholic fatty liver disease (NAFLD) patients with normal alanine aminotransferase (alt): data from a large North American primary care NAFLD pathway	Abdel Aziz Shaheen	Received

LBP-005	Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection	Lisa Danzig	Received

THU-006	NASH is emerging as a leading cause of hospitalisation for cirrhosis: results from a real-life, prospective, consecutive cohort	Christiane Stern	Received

FRI-006	Non-invasive detection of NASH and significant fibrosis in NAFLD patients with low FIB-4	Heike Bantel	Received

SAT-006	AXL inhibition prevents NAFLD progression in mice with soluble AXL as marker of the NAFLD to NASH transition	Anna Tutusaus	Received

LBP-007	Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study	Behzad Hajarizadeh	Received

SAT-007	Efficacy and safety of an acetyl CoA carboxylase inhibitor are improved in combination with PPAR agonists in a dyslipidemic rat model	ARCHANA VIJAYAKUMAR	Received

LBP-008	faecal microbiota transplantation reduces pathogenic burden and is anti-inflammatory in patients with advanced cirrhosis	Lindsey Ann Edwards	Received

FRI-008	Predictive modelling to identify and characterize fast progressors among patients with non-alcoholic steatohepatitis (NASH)	Brenda Reinhart	Received

FRI-009	Non-invasive tests for assessing fibrosis in patients with non-alcoholic fatty liver disease: an evaluation of combining test results	Sari Rizk	Received

SAT-009	Adipose tissue macrophages acquire a pro-inflammatory phenotype which is associated to liver fibrogenesis in an experimental model of NAFLD in mice	Celia Martínez Sánchez	Received

THU-009	Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis from chronic hepatitis C who achieved a sustained virologic response	Elizabeth Artwick	Received

LBP-009	The impact on mortality of a national hepatitis C elimination program, Georgia, 2015-2019	Lia Gvinjilia	Received

FRI-010	13c-octanoate breath test in a predictive score for the diagnosis of non-alcoholic steatohepatitis	Carmen Fierbinteanu Braticevici	Received

LBP-010	Bariatric surgery is not associated with a reduction in risk of severe liver disease in comparison to standard obesity treatment in 3,922 subjects	Hannes Hagstrm	Received

SAT-010	Intermittent hypoxia featuring the obstructive sleep apnea syndrome contributes to hepatosteatosis by upregulating the intrahepatic expression of fatty acid translocase CD36 and lipogenic genes	Carmelo Garcia-Monzon	Received

THU-010	PNPLA3 gene polymorphism and overall and cardiovascular mortality among non-alcoholic fatty liver disease in the United States	Karn Wijarnpreecha	Received

SAT-011	The symbiotic supplementation modulate gut microbiota, regulation beta-catenin expression and prevents weight gain in ob/ob mice with non-alcoholic fatty liver disease (NAFLD)	Claudia Oliveira	Received

FRI-011	Interplay between metabolic derangement, biomarkers of collagen remodeling and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease	Chiara Rosso	Received

LBP-012	Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data	Harry Janssen	Received

SAT-012	Treatment with the endothelin receptor inhibitor bosentan alleviates the NAFLD-associated increased intrahepatic vascular resistance and reduces steatosis and liver damage in a rat model of early NAFLD	Denise van der Graaff	Received

LBP-013	A Phase 2 Study of Peginterferon Lambda, Lonafarnib and Ritonavir for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study	Christopher Koh	Received

FRI-013	Mack-3: an accurate blood test for the diagnosis of fibrotic NASH and a candidate biomarker to monitor disease progression	Clémence Canivet	Received

FRI-014	Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD score) on NAFLD in a mixed Latin American population	Claudia Oliveira	Received

LBP-014	Proof-of-concept use of machine learning to predict tumor recurrence of early-stage hepatocellular carcinoma before therapy using baseline magnetic resonance imaging	Ahmet Said Kckkaya	Received

SAT-014	Identification of novel biomarkers and therapeutic targets for steatohepatitis and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD): an in silico analysis	Douglas Maya-Miles	Received

LBP-015	Hepatocyte-specific deficiency of sphingosine kinase 1 exacerbates acetaminophen-induced liver injury	Tian Lan	Received

SAT-015	Liver-chip: a model for understanding diet-induced liver disease and drug efficacy assessment	James Trevaskis	Received

FRI-015	Identification of significant fibrosis in patients with non-alcoholic steatohepatitis using non-invasive tests: determination of optimal thresholds based on cross-sectional analyses of patients screened for a phase 3 randomised controlled trial	Darshini Shah	Received

LBP-016	MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study	Hubert Chen	Received

THU-016	Prevalence of non-alcoholic fatty liver in the Netherlands: the Netherlands Epidemiology of Obesity study	Gabrielle Alblas	Received

FRI-016	Patients with non-alcoholic fatty liver disease referred from primary care have a significant serum fibrosis marker and liver stiffness measurement discordance	David Harman	Received

LBP-017	BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomized, double-blind, placebo-controlled trial	Elizabeth Artwick	Received

SAT-017	Propionate intervention attenuates NASH while negatively affecting cognition	Eveline Gart	Received

THU-017	Association between non-alcoholic fatty liver disease and nut consumption	Georg Semmler	Received

LBP-018	JKB-122 in subjects with non-alcoholic fatty liver disease (NAFLD): a phase 2, randomized, multiple-dose, double-blind, placebo-controlled study	Sheng-Hung Liu	Received

THU-018	Myosteatosis and sarcopenia are prevalent in patients with NAFLD even in the absence of advanced fibrosis	Giada Pallini	Received

SAT-018	A shortcut from non-alcoholic fatty liver disease to HCC: c-Myc, a promising theranostic target	Feifei Guo	Received

FRI-018	Digital image analysis for quantitative evaluation of fibrosis, steatosis, inflammation and iron overload in patients with non-alcoholic fatty liver disease	David Marti-Aguado	Received

LBP-019	Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study	Ashley Sowers	Received

SAT-019	Sex differences of adipose tissue dynamic changes in NASH progression of morbid obese patients: a preliminary study	Gerard Baiges	Received

THU-019	A cholestatic pattern predicts liver outcomes in patients with non-alcoholic fatty liver disease	Grazia Pennisi	Received

FRI-020	Metabolomics composite biomarkers ed by machine learning predicts NASH	Samuel Hellings	Received

SAT-020	Hepatocyte-specific deletion of ERK5 worsens insulin resistance in a murine model of non-alcoholic fatty liver disease (NAFLD)	Giovanni Di Maira	Received

LBP-021	Serum-based Metabolomics-Advanced StEatohepatitis Fibrosis Score (MASEF) fot the non-invasive identification of patients with non-alcoholic steatohepatitis with significant fibrosis	Mazen Noureddin	Received

THU-021	Serum zinc level and liver fibrosis in male patients with non-alcoholic fatty liver disease	Won Sohn	Received

FRI-021	Diagnostic accuracy of acoustic radiation force impulse elastography for the staging of hepatic fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis	Emmanuel Selvaraj	Received

SAT-021	MicroRNAs involved in the progression of non-alcoholic fatty liver	Guillermo Nahúm López-Sánchez	Received

LBP-022	Screening for non-alcoholic fatty liver disease in persons with type 2 diabetes in the U.S. is cost effective: A comprehensive economical analysis	Eric Mitchell	Received

SAT-022	Simultaneous intra-operative sampling from multiple anatomical sites reveals pro-inflammatory liver homing T cells in liver, adipose tissue and peripheral blood in patients with NASH	James Brindley	Received

FRI-022	Three is enough: optimization of regions of interest ion for accurate estimation of proton density fat fraction in liver from magnetic resonance images	Florent Roche	Received

THU-022	Identification of factors associated with engagement and adherence to a very low calorie diet to achieve significant weight loss in patients with advanced non-alcoholic fatty liver disease: a qualitative evaluation	Jadine Scragg	Received

SAT-023	The influence of obesity, non-alcoholic steatohepatitis and bariatric surgery on plasma lipid profile	Helena Castañé	Received

THU-023	Lack of histological steatohepatitis features in advanced fibrosis could impact in screening failure rate: a comparison with FDA clinical criteria	Javier Ampuero	Received

LBP-023	CHESS criteria for the screening of varices in patients with compensated advanced chronic liver disease: a multicenter study	Xiaolong Qi	Received

FRI-023	Diagnostic accuracy of magnetic resonance elastography for the staging of fibrosis and diagnosis of steatohepatitis in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis	Ferenc Mozes	Received

FRI-024	Investigation of a composite imaging biomarker for identification of non-alcoholic steatohepatitis (NASH) patients in a Japanese population	Louise Tetlow	Received

THU-024	Risk factors associated to NAFLD-related advanced fibrosis in patients with normal ALT levels	Javier Ampuero	Received

LBP-025	A novel immunoregulatory role for complement receptor C3AR1 in fibrosing cholangiopathies of biliary atresia and primary sclerosing cholangitis	Pranavkumar Shivakumar	Received

SAT-025	The influence of TRPM8 variant on brown adipose tissue activity and contribution to increased susceptibility to non-alcoholic fatty liver disease among South Asians	JANE GROVE	Received

THU-025	Fibrosis quantification by image morphometry of liver fibrosis predicts clinical outcomes in patients with non-alcoholic fatty liver disease	Zhengyi Wang	Received

LBP-026	Resolution of non-alcoholic steatohepatitis and hepatic fibrosis by sodium glucose transporter-2 inhibitor, ipragliflozin; a multicenter randomized controlled trial	Hirokazu Takahashi	Received

FRI-026	The prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus	Leen Heyens	Received

LBP-027	Novel markers to predict virological and clinical relapse onset following antiviral treatment discontinuation in chronic hepatitis B patients	Marianne Tuefferd	Received

FRI-027	Validation of interleukin-32 as a new circulating fatty liver biomarker	Guido Alessandro Baselli	Received

FRI-028	Simple non-invasive prediction of advanced fibrosis in NAFLD - a stepwise approach and external validation study to reduce indeterminates and biopsy	Heather Kosick	Received

LBP-028	Noninvasive point-of-care 13C-Methacetin Breath Test (MBT) predicts risk of clinical deterioration independently of currently used prognostic indicators in patients with decompensated NASH cirrhosis	Raffi Werner	Received

SAT-028	High-throughput sequencing identified MIR-193a as a potential biomarker of non-alcoholic fatty liver disease activity	Katherine Johnson	Received

THU-028	The association with low skeletal muscle mass and carotid atherosclerosis in patients with non-alcoholic fatty liver disease	Min Kyu Kang	Received

SAT-029	Ageing causes lipid metabolism imbalance and exacerbates steatohepatitis in high-fat diet-fed mice	Kazuyoshi Kon	Received

FRI-029	Adherence to established process measures in the evaluation of hepatic steatosis on imaging in a large tertiary care network	Hersh Shroff	Received

THU-029	Gender difference and hepatocellular carcinoma incidence in non-alcoholic steatohepatitis patients with advanced liver fibrosis	Kanokwan Pinyopornpanish	Received

LBP-030	Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study	Lisa Danzig	Received

THU-030	Advanced liver fibrosis predicts poor cardiovascular outcomes in patients with type 2 diabetes	Ho Soo Chun	Received

FRI-030	Value of FIB-4 and NAFLD fibrosis scores for screening of liver fibrosis in the general population	Isabel Graupera	Received

LBP-031	Machine learning identifies histologic features associated with regression of cirrhosis in treatment for chronic hepatitis B	Oscar Zevallos	Received

FRI-031	Utilizing pre-existing imaging and data lake technology in the search of clinically neglected non-alcoholic fatty liver disease (NAFLD)	Iiro Karhiaho	Received

THU-031	Histological renal damage and eligibility for kidney donation are worse in patients with biopsy-proven non-alcoholic steatohepatitis compared with simple steatosis	Lorenzo Mulazzani	Received

FRI-032	Factors associated with NAFLD and advanced liver fibrosis and accuracy of liver biopsy in patients with diabetes mellitus type 2: a cross sectional study	Ivana Mikolasevic	Received

LBP-032	Long-term survival of repeat hepatic resection and radiofrequency ablation for patients with recurrent hepatocellular carcinoma: a multicentric study	Jian-Hong Zhong	Received

SAT-032	Anti-inflammatory and anti-fibrotic activity of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, in a rat choline-deficient high-fat diet non-alcoholic steatohepatitis model	Martijn Fenaux	Received

SAT-033	Cognitive dysfunction occurs early in experimentally induced NAFLD and is associated with systemic inflammation	Kristoffer Kjrgaard	Received

FRI-033	FIB-4 first strategy for non-alcoholic fatty liver disease might not be appropriate for ruling-out advanced liver fibrosis with current cut-off values in patients with type 2 diabetes mellitus	Ivica Grgurevic	Received

THU-033	Incidence and risk factors for cardiovascular events in patients with advanced fibrosis due to non-alcoholic steatohepatitis: data from the phase 3 STELLAR trials	Marianne Camargo	Received

LBP-033	Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and REP 401 studies	Andrew Vaillant	Received

FRI-034	Accuracy of cytokeratin-18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis	Jenny Lee	Received

SAT-034	Thr -ive agonist MGL-3196 improves NAS score and plasma lipoprotein profile in the liver-humanized FRGN KO NASH model	LANDER FOQUET	Received

THU-034	A substantial number of patients with non-alcoholic fatty liver disease and type 2 diabetes have advanced liver fibrosis with a normal serum alanine transaminase	Michael Patrick Johnston	Received

SAT-035	TM6SF2/PNPLA3/MBOAT7 loss-of function genetic variants impact on NAFLD development and progression both in patients and in in vitro models	Miriam Longo	Received

THU-035	Unlike HbA1c level and the amount of visceral adipose tissue, the presence and severity of NAFLD do not predict the occurrence of major adverse cardiovascular events in an obese Belgian population	Mikhail Van Herck	Received

FRI-036	Composite biomarkers ed by machine learning predict severe fibrosis in NASH	Christina Ebert	Received

THU-036	Association of FIB-4 score with disease progression in real-world populations diagnosed with NAFLD/NASH or at risk of NASH in US clinical practice	Michelle Lai	Received

SAT-036	Enhancing autophagy improves and slows the progression of non-alcoholic steatohepatitis disease	Maria Ruart Millán	Received

SAT-037	The PSRC1 rs599839 AG variant disentangles the risk of coronary artery disease and hepatocellular carcinoma in Italian NAFLD patients	Marica Meroni	Received

THU-037	Association of FIB-4 score with major cardiovascular events (MACE) in real-world populations diagnosed with NASH or NAFLD in US clinical practice	Michelle Lai	Received

SAT-038	The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH	Marie OFarrell	Received

FRI-038	Phenome-wide association study of the FIB-4 index in a large, populational-based study in the United States	Andrew Billin	Received

THU-038	Relevance of social support and severity of liver disease in biopsychosocial profiles of patients with non-alcoholic fatty liver disease	Jesús Funuyet-Salas	Received

FRI-040	Macrophage markers do not add to the prediction of liver fibrosis by transient elastography in patients with non-alcoholic fatty liver disease	Konstantin Kazankov	Received

SAT-041	Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation in non-alcoholic fatty liver disease	Marta B. Afonso	Received

FRI-041	Diagnostic accuracy of controlled attenuation parameter compared to ultrasound for detecting steatosis in children with obesity	Laura Draijer	Received

THU-041	Muscle fat infiltration in obese patients is associated with NAFLD related fibrosis severity - results from a prospective imaging study	Nicolas Lanthier	Received

THU-042	Exercise performance in patients with non-alcoholic steatohepatitis	Oliver Glass	Received

SAT-042	A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and rodent NASH and liver injury models	Mary Chau	Received

FRI-042	ELF test should be used concurrently with elastography in NAFLD to maximize diagnostic accuracy	Laura Iogna Prat	Received

FRI-043	Evaluation of a novel histology-based fibrosis phenotypic composite score and its correlation with NASH-CRN fibrosis scores in patients with NASH	Li Chen	Received

THU-044	Obesity and alcohol intake modify the impact of genetic variants on the risk for incident liver disease in the general population	Panu Luukkonen	Received

FRI-044	Serum exosomal miRNA-4668-5p as potential biomarker for advanced fibrosis in non-alcoholic fatty liver disease	Young-Sun Lee	Received

SAT-044	Efficacy and safety of combination therapy with elobixibat and colestyramine for non-alcoholic steatohepatitis model mice	Michihiro Iwaki	Received

SAT-045	The role of RIPK3 in non-alcoholic fatty liver disease: a multi-omics perspective	Miguel Mateus-Pinheiro	Received

FRI-046	Patient-reported symptoms and impact in non-alcoholic steatohepatitis: an evaluation of the NASH-check, a novel prom in NASH	Ramakrishna GS	Received

THU-046	Barriers and motivators to engaging in physical activity in individuals with NAFLD: implications for physical activity adherence	Philip OGorman	Received

SAT-046	Muscle fat is higher in NAFLD, and increases with fibrosis stage - a retrospective liver biopsy controlled magnetic resonance imaging-based body composition study	Mikael Forsgren	Received

THU-047	Serious complications due to study-mandated liver biopsies in phase 3 trials for patients with advanced fibrosis due to non-alcoholic steatohepatitis	Kathryn Kersey	Received

FRI-047	The FGF19 analogue aldafermin improves non-invasive tests in patients with non-alcoholic steatohepatitis	Marno Ryan	Received

SAT-047	Adoptive cell transfer of regulatory T cells causes an exacerbation of hepatic steatosis in high-fat high-fructose diet-fed mice	Mikhail Van Herck	Received

THU-048	The burden of disease associated with non-alcoholic steatohepatitis patients under standard of care	Sari Rizk	Received

FRI-048	Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis	Ramakrishna GS	Received

SAT-048	Synergic effect of a combined treatment with atorvastatin and ambrisentan in a rat model of NASH	Miren Bravo	Received

THU-049	Insulin secretion is an independent predictor of hepatic ballooning in non-diabetic subjects with non-alcoholic fatty liver disease	Ramy Younes	Received

SAT-049	Obesity and non-alcoholic steatohepatitis: assessing lipid diversity in adipose tissue	Montserrat Fibla Simó	Received

THU-050	NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients	Rosa Lombardi	Received

FRI-050	Liver incytes: assessment of fibrosis and steatosis in patients and healthy volunteers	Michael Curry	Received

SAT-051	Blocking IL-1 signaling in hepatocytes undergoing metabolic stress protects against metabolic inflammation and attenuates pro-coagulant factors	Nadine Gehrke	Received

FRI-051	Analysis of the prevalence of metabolic syndrome components and other factors as predictors of disease progression among an urban population with NAFLD and/or NASH	Magdy Elkhashab	Received

FRI-052	The impact of ethnicity on incidence of NAFLD/NASH among patients referred to the Toronto liver centre for non-invasive evaluation with transient elastography	Magdy Elkhashab	Received

SAT-052	Monocyte chemoattractant protein-induced protein 1 level negatively correlates with steatosis in fatty liver patients	Natalia Pydyn	Received

THU-052	Clinical and economic impact of non-alcoholic fatty liver disease in Spain	María Sainz	Received

FRI-053	Drivers of diagnosis and referral decisions in non-alcoholic fatty liver disease patients	martina klinger sikora	Received

THU-053	Europes largest meta-analysis on the prevalence of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and advanced fibrosis (F3-F4)	Diogo Ferrinho	Received

SAT-053	Ultrastructural changes in perfusion-fixed human non-alcoholic fatty liver disease biopsies	Pauline Verhaegh	Received

FRI-054	Validation of the accuracy of the fast score for detecting non-alcoholic steatohepatitis patients at high risk of becoming cirrhotic in a North American cohort	Tinsay Woreta	Received

THU-054	Patients receiving liver transplant for NASH cirrhosis have greater muscle loss compared to transplant and non-transplant control	Samarth Patel	Received

SAT-054	mIR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD	Rodrigues Pedro	Received

SAT-055	Inhibition of autotaxin-lysophosphatidic acid signaling pathway by a novel autotaxin inhibitor FP10.47 ameliorates non-alcoholic steatohepatitis in vivo	Richell Booijink	Received

FRI-055	Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population	Monika Lewinska	Received

THU-055	A national cross-sectional survey of health-related quality of life in Chinese patients with non-alcoholic fatty liver disease	Rui Huang	Received

THU-056	Risk factors associated with subclinical atherosclerosis in the patients with biopsy-proven non-alcoholic fatty liver disease	Taeang Arai	Received

FRI-056	Difference between antinuclear antibody-positive non-alcoholic steatohepatitis and autoimmune hepatitis based on differential patterns of peripheral T lymphocytes	Akira Kado	Received

SAT-056	Recombinant glutamine synthetase reduces ammonia and hepatic fibrosis in in vitro and in vivo models of non-alchoholic fatty liver disease	Antria Siakalli	Received

THU-057	Progression of non-alcoholic fatty liver disease is rare in a Danish tertiary liver centre	Tea Lund Laursen	Received

FRI-057	Utility of metabolomic biomarkers to identify non-alcoholic fatty liver disease in liver transplant recipients	Christopher Mowry	Received

FRI-058	Cost-effectivity analysis of several non-invasive test strategies for detection and referral of patients with non-alcoholic fatty liver disease at risk of advanced fibrosis	Bianca Sánchez	Received

SAT-058	GPNMB modulates hepatic steatogenesis and liver cancer	Seddik Seddik Hammad	Received

FRI-059	Prediction of advanced fibrosis with transient elastography is superior to gut microbiota-based approaches in non-alcoholic fatty liver disease	Sonja Lang	Received

SAT-059	TM6SF2 E167K variant increases the severity of NAFLD in high fat diet-fed mice	Shousheng Liu	Received

FRI-060	The accuracy of the fast score in predicting NASH with significant fibrosis	Nabil Noureddin	Received

SAT-060	Unrevealing the HDL lipidome in NAFLD: a possible explanation for the increased CVD risk of these patients	Sofia Kartsoli	Received

THU-060	First 1-year follow up data from the German NAFLD prospective real-life cohort (FLAG study) show low frequencies of lifestyle changes	Wolf Peter Hofmann	Received

SAT-061	A novel small molecule modulating the mitochondrial NEET (CISD) proteins activity improves inflammation and fibrosis in a diet-induced model of non-alcoholic steatohepatitis	Stéphanie Le Corre	Received

THU-061	Fibrosis non-invasive tests capture changes in patient-reported outcomes of patients with advanced non-alcoholic steatohepatitis	Carey Escheik	Received

THU-062	Gut transcriptomics reveals potential therapeutic strategies for the restoration of epithelial barrier repair in alcohol-related liver cirrhosis	Antonio Riva	Received

FRI-062	Expanding the use of the vibration controlled transient elastography in morbid obese patients: validation of a new automated adaptive measurement depths algorithm in a large pooled NAFLD cohort	Anne LLORCA	Received

THU-063	Specific alterations of the immune checkpoint secretome are linked with antibacterial immunity in alcohol-related liver disease	Antonio Riva	Received

FRI-064	Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH	Peter Mesenbrink	Received

THU-064	Proton pump inhibitors increase the risk of oral cancer among patients with alcoholic cirrhosis	Astrid Hjmark Andersen	Received

THU-065	Analysis of the influence of alcoholic abstinence on mortality in patients with alcoholic liver cirrhosis	Ángela Suárez-Noya	Received

SAT-065	Infiltrative monocyte derived adenosine deaminase 2 promotes liver fibrosis via signaling through extracellular inosine	Shilpa Tiwari Heckler	Received

FRI-065	Liver derived apoptotic microparticles as biomarkers to detect transition from simple steatosis to steatohepatitis in non-alcoholic fatty liver disease	Rocío Muñoz	Received

FRI-066	Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the regenerate trial	Sari Rizk	Received

THU-066	Non-invasive criteria for diagnosis of alcoholic hepatitis: use in clinical practice and correlation with prognosis	Emma Avitabile	Received

SAT-066	TERN-501, a potent and ive agonist of thyroid hormone receptor beta, strongly reduces histological features and biomarkers of non-alcoholic steatohepatitis associated pathology in rodent models	Martijn Fenaux	Received

FRI-067	Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease	Salvatore Petta	Received

FRI-068	Glympse liver test for noninvasive monitoring of combination drug therapy in a rat model of non-alcoholic steatohepatitis (NASH)	Sophie Cazanave	Received

THU-068	Alcohol recurrence and outcome in patients transplanted for alcoholic cirrhosis: impact of the 6-month rule	Claire Perignon	Received

SAT-069	Chorionic-plate-derived mesenchymal stem cells attenuate hepatic steatosis via restoration of mitochondrial function	Yun Bin Lee	Received

FRI-069	Too many to refer? FIB-4 scores in primary care patients with abnormal liver tests	Andrew Schreiner	Received

THU-069	Early liver transplantation in active drinkers with and without alcoholic hepatitis: a monocentric case series	Debora Angrisani	Received

THU-070	Long-term outcome of symptomatic alcoholic hepatitis with a Maddrey discriminant function 32	Degré Delphine	Received

FRI-070	Circulating pcsk9 levels correlated with advanced disease in patients with biopsy-proven non- alcoholic fatty liver disease	Sheila Gato Zambrano	Received

THU-071	Genetic variant PNPLA3 I148M accelerates fat accumulation in livers of mice with ASH/NASH via damping of PPAR alpha and PPAR gamma signalling pathways	Eleonora Patsenker	Received

FRI-071	Non-invasive liver fibrosis markers, FIB-4, PRO-C3 and ADAPT, are significantly elevated in biopsy confirmed NAFLD patients at high risk of developing coronary heart disease and cardiovascular disease and are promising clinical decision making tools	Samuel Daniels	Received

THU-072	Delisting of liver transplant candidates after improvement in alcohol-related decompensated cirrhosis: a multicentric study on incidence and outcomes	Gonzalo Crespo	Received

FRI-072	The FIB-8 score: validation of a model to screen patients with non-alcoholic fatty liver disease for significant fibrosis	Pimsiri Sripongpun	Received

FRI-073	Continuous CAP algorithm: reduced variability in a prospective cohort	Anne LLORCA	Received

FRI-074	Ultrasound small vessel imaging and deep learning; a novel approach to FLD screening	Tim Hoogenboom	Received

THU-074	Alcohol use disorder and liver fibrosis - cases are missed through failure to test	Freya Rhodes	Received

THU-075	Decreasing incidence of alcoholic liver disease in Denmark: a nationwide study	Frederik Kraglund	Received

FRI-075	Individual patient data meta-analysis on controlled attenuation parameter for the XL probe in obese patients	Thomas Karlas	Received

SAT-076	Application of the new GLIM criteria for the diagnosis of malnutrition in patients with liver cirrhosis and usefulness of three different screening tools	Diego Casas Deza	Received

THU-076	Fibroblast growth factor 21 response in a preclinical model of alcohol induced acute-on-chronic liver injury	Grigorios Christidis	Received

SAT-077	Automated low flow ascites (ALFA) pump effectively reduces the number of large volume paracentesis - data from a real world cohort	Adam Herber	Received

THU-077	Mortality in biopsy-proven alcohol-related liver disease: population-based cohort study of 3,453 individuals	Hannes Hagstrm	Received

FRI-077	Optimal non-invasive screening strategy for non-alcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes	Veeral Ajmera	Received

SAT-078	Covered TIPSS does not improve long term survival in refractory ascites - a single- centre experience	Amritpal Dhaliwal	Received

THU-078	Inhibition of cytochrome P-4502E1 by clomethiazole improves alcoholic liver disease in alcohol-dependent patients: a short-term, randomized, controlled clinical trial	Helmut Seitz	Received

FRI-079	Use of the fibrosis-4 score to estimate fibrosis stage for patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in retrospective real-world datasets: a targeted literature review and feasibility assessment	Elizabeth Artwick	Received

FRI-080	Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study	Sari Rizk	Received

SAT-080	PPIs can be discontinued in over 60 of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions	Alison Boyle	Received

SAT-081	Building a better mousetrap: can MELD-Na be improved?	Allison Kwong	Received

THU-081	In alcoholic hepatitis, cytokeratin 18 serum fragments reflect its severity and predict responsiveness to prednisolone	JANE GROVE	Received

FRI-081	Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians	Carey Escheik	Received

FRI-082	A randomized, double blind, placebo-controlled trial of htd1801 (berberine ursodeoxycholate, budc ) in patients with hypercholesterolemia: implications for its use in non-alcoholic steatohepatitis (NASH)	Jeffrey Dao	Received

SAT-082	Systemic inflammation is associated with cardiodynamic state in acute-on-chronic liver failure	Sofia Monteiro	Received

SAT-083	Preliminary results of the effects of beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: a randomized controlled pilot study	Angelo Bruni	Received

THU-084	Pharmacokinetics of DUR-928 in alcoholic hepatitis patients - a phase 2a study	Jaymin Shah	Received

FRI-084	Gw9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease	Anja Baumann	Received

SAT-084	Optimizing nutrition in patients with cirrhosis may reduce hospital readmissions in medium and high risk groups: a quality improvement project	Angela Liaros	Received

SAT-085	Adipopenia, among the nutritional parameters, is the rapid screening tool that best correlates with mortality in decompensated cirrhotic patients: results of a prospective study	Anna Lombardi	Received

FRI-085	Obesity management during the rise of NAFLD: real world outcomes of the medical weight loss approach using a very low energy diet	Ann Farrell	Received

FRI-086	Supplementing diet with olive oil does not prevent the progression of non-alcoholic fatty liver disease	Annette Brandt	Received

SAT-086	Leptin as a key player in insulin resistance of liver cirrhosis	Anna Mrzljak	Received

SAT-087	Femur fractures are associated with high morbimortality in patients with cirrhosis	Anna Brujats	Received

SAT-088	The presence of infection during hospitalization is associated with an increased risk of procedure-related bleeding in cirrhosis	Abhishek Shenoy	Received

FRI-088	Single doses of TERN-201, a novel ive semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in sustained reduction of SSAO activity in healthy participants	Martijn Fenaux	Received

FRI-089	Decline in NASH and atherosclerosis-associated oxidised phospholipids and 7-ketocholesterol in response to icosabutate therapy	David A. Fraser	Received

SAT-089	Role of urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1 and cystatin C as markers of mild kidney function impairment in patients with liver cirrhosis	Anna Szymanek-Pasternak	Received

SAT-090	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with V2-receptor antagonist for hepatic edema	Koichi Takaguchi	Received

THU-090	High risk of futile over-referrals or late under-referrals among patients suspected of alcohol-related or non-alcohol-related fatty liver disease: real-world evidence reveal opportunities to optimize referral patterns to secondary care	Katrine Prier Lindvig	Received

FRI-090	Aramchol improves glucose and lipid homeostasis in NASH via regulation of AMPK and mTOR	Cristina Alonso	Received

FRI-091	Saroglitazar for the treatment of NAFLD patients: a single- center observational study at 52 weeks follow up	Santosh Hajare	Received

THU-091	Patients with alcoholic hepatitis present strong Th1 cellular immune responses to alcohol dehydrogenase related to impairment of the PD-1/PD-L1 pathway due to high circulating levels of soluble PD-1	Laura Blackmore	Received

SAT-091	Combination of meld and lactates predicts early death in patients treated by salvage tips for refractory variceal bleeding	Aurélie Walter	Received

THU-092	Differential roles of receptor interacting protein 3 and mixed lineage kinase like in murine models and patients with alcohol- and non-alcohol related liver disease	Tatsunori Miyata	Received

FRI-092	The pharmacokinetics, pharmacodynamics, and short-term safety of cilofexor, a nonsteroidal farnesoid X receptor agonist, in subjects with hepatic impairment	Elijah Weber	Received

SAT-092	Esophageal varices recurrence after eradication: are there any predictors ?	Myriam Ayari	Received

FRI-093	Concentration-QT analysis of firsocostat, a liver-targeted acetyl-coa carboxylase inhibitor	Elijah Weber	Received

FRI-094	The safety and pharmacokinetics of fenofibrate in patients with advanced fibrosis including those with non-alcoholic steatohepatitis (NASH)	Elijah Weber	Received

THU-094	Defective gut adaptive immunity during early alcoholic liver disease	Luca Maccioni	Received

THU-095	Metabolic and genetic risk factors predict advanced alcohol-related liver fibrosis regardless of drinking pattern	Mads Israelsen	Received

SAT-095	Risk factors associated with mortality in upper gastrointestinal bleeding in cirrhotic patients	Andra Barbulescu	Received

SAT-096	Epithelial cell death markers M65 and M30 are significantly up-regulated in decompensated liver cirrhosis and decreased by correction of portal hypertension	Beatrice-Victoria Jahn	Received

FRI-096	A randomized, double-blind, placebo-controlled, first-in-human single ascending dose, multiple ascending dose, and food effect study to evaluate the safety, tolerability, and pharmacokinetic profile of FM101 in healthy volunteers	Seon-Ah Ha	Received

THU-097	The development and severity of alcoholic hepatitis is associated with decreased intestinal microbiome-derived secondary bile acid isoursodeoxycholic acid	Katarina Gluic	Received

SAT-097	Bidimensional shear wave elastography of the rectus femoris muscle in patients with cirrhosis	Chiara Becchetti	Received

FRI-097	Direct access lifestyle training improves liver biochemistry and causes weight loss but uptake is suboptimal in patients with NAFLD	Imran Patanwala	Received

SAT-098	Bacterial translocation-induced inflammation promotes liver fibrogenesis in patients with advanced chronic liver disease	Benedikt Simbrunner	Received

FRI-099	The efficacy of vitamin D supplementation on NAFLD: a randomized, double-blind, placebo-controlled 12- month trial on 311 patients	Ivana Mikolasevic	Received

SAT-099	Rotational thromboelastometry (rotem)-based assessment of coagulopathy in cirrhotic patients stratified by severity of portal hypertension	Benedikt Simbrunner	Received

SAT-100	Impact of extended- spectrum- beta- lactamase faecal carrier on cirrhotic patients: a retrospective study on clinical outcomes before and after liver transplantation	Bianca Magro	Received

FRI-100	Molecular, cellular, and pharmacological characterization of beta-ive partial agonists of human thyroid hormone receptor for the treatment of non-alcoholic steatohepatitis	Jerome Deval	Received

THU-101	Unexpected protective role of the chemokine lix after Gao-binge ethanol feeding in mice	Kyle Poulsen	Received

SAT-101	A randomized, double-blind study to evaluate the safety and tolerability of KB174, a novel synthetic glycan, in patients with well-compensated cirrhosis	Robin Raskin	Received

SAT-102	Renal clearance measured by iohexol identifies cirrhotic patients with normal creatinine at risk of serious adverse events	Carlos González-Alayón	Received

THU-102	Shedding light on BASH: a novel experimental model of advanced liver damage	Raquel Benedé	Received

FRI-102	Efficacy and feasibility of a very low calorie diet to achieve 10 weight loss in patients with advanced non-alcoholic fatty liver disease	Kate Hallsworth	Received

SAT-103	Clinical relevance of sarcopenia in liver transplant candidates	Chiara Mazzarelli	Received

THU-103	Duration of alcohol abstinence as a predictor of alcohol relapse - the more the better?	Ricardo Crespo	Received

FRI-104	The effectiveness of Mediterranean diet versus calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review with clinical implications	Laura Haigh	Received

SAT-104	Impact of non-ive beta-blockers on hepatic encephalopathy in patients with liver cirrhosis	Christian Labenz	Received

FRI-105	Therapeutic efficacy of the chitotriosidase inhibitors in STAM model of non-alcoholic steatohepatitis	Michal Mlacki	Received

THU-105	Comparitive hepatic proteome analysis in low and high dose ab libitum alcohol mice model of liver injury	Sudrishti Chaudhary	Received

SAT-105	Characterization of alterations in mechanical, thermal and pain sensitivity in cirrhotic patients with minimal hepatic encephalopathy	Carmina Montoliu	Received

FRI-106	Endoscopic gastric plication (endosleeve) improves hepatic steatosis and liver fibrosis in patients with grade 1-2 obesity, preliminary results at 6 months	Michel Ble	Received

SAT-106	Role and prognostic value of routine doppler sonography in patients with severe liver disease - a prospective cohort study in an intensive care unit	Constantin Maier-Stocker	Received

SAT-107	Lack of evidence of significant tubular injury in patients with cirrhosis and persistent hepatorenal syndrome. implications for liver transplantation	Cristina Solé Martí	Received

FRI-107	Use of GLP-1 receptor agonists (GLP1A) and/or SGLT-2 inhibitors (SGLT2I) in populations with NASH or at risk of NASH in US clinical practice	Michelle Lai	Received

SAT-108	Hepatic and splenic elastography: are they predictors of recurrence of esophageal varices after complete eradication?	Daniela Reis	Received

FRI-108	BIO89-100, a novel glycopegylated FGF21 analog, reduces body weight and fat mass in naive CD-1 mice through an increase in energy expenditure despite an increase in food consumption	Moti Rosenstock	Received

THU-108	Plasma protein glycomics combined with circulating fragments of cytokeratin-18 are reliable biomarkers to diagnose alcoholic hepatitis	Verhelst Xavier	Received

SAT-109	Risk of contrast-induced acute kidney injury in cirrhotic patients undergoing computed tomography: myth or reality?	Daniela Campion	Received

THU-110	Single-cell analysis of self-antigen-specific CD4 T cells reveals the B helper signature and the peripheral reservoir of autoreactive T cells in autoimmune hepatitis	Amédée Renand	Received

FRI-110	Characterization of EYP001 a novel, potent and ive FXR agonist in in vitro 3D human liver models of NASH	Pauline RADREAU-PIERINI	Received

THU-111	FXR agonists repress innate and adaptive effector cytokine production in primary sclerosing cholangitis	Astha Malik	Received

FRI-111	Synergistic effect of clostridium butyricum miyairi on rifaximin in mice model of non-alcoholic steatohepatitis by methionine choline-deficient diet	Ryo Yamauchi	Received

SAT-112	Serologically assessed fragments of type VI collagen are predictors of progression free survival and death in patients with hepatocellular carcinoma	Diana Leeming	Received

FRI-112	Methylnaltrexone and rifaximin treatments significantly improve chronic leaky gut in a diet-induced mouse model of non-alcoholic fatty liver disease	Katie Rogers	Received

FRI-113	Recombinant glutamine synthetase (AM-535): a novel therapeutic approach for the treatment of hyperammonaemia and its deleterious effects on multiple systems	Antria Siakalli	Received

THU-113	Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through modulating hepatic and intestinal inflammatory signaling	Claudia Fuchs	Received

THU-114	Predicted risk of end stage liver disease utilizing the UK-PBC risk score with continued standard of care and subsequent addition of obeticholic acid for 60 months in patients with primary biliary cholangitis	Sari Rizk	Received

FRI-114	Co-administration of PF-05221304 and PF-06865571 delivers robust whole liver fat reduction and mitigation of acetyl-coa carboxilase inhibitor induced hypertriglyceridemia in patients with NAFLD	Roberto Calle	Received

FRI-115	A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (HM15211) in healthy obese subjects	Seungjae Baek	Received

THU-115	Cell specific transcriptomic analysis reveals a disassociation between treatment response and peripheral markers of immune activation in primary biliary cholangitis	Victoria Mulcahy	Received

THU-116	Distinct intrahepatic molecular signature between relapse and sustained remission of autoimmune hepatitis before initiation of immunosuppression withdrawal	Bastian Engel	Received

SAT-116	PROSPER study reveals reduction in bed days per hospitalisation and decreased risk of mortality for patients observed on rifaximin-alpha 550mg compared to a cohort on standard of care	Dave Walker	Received

FRI-116	Change in hepatic output of palmitic acid after weight loss in type 2 diabetes	Shaden Melhem	Received

FRI-117	GLP-1/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model	Scott Harris	Received

THU-117	Metagenomic sequencing in primary sclerosing cholangitis highlights microbial metabolism of essential nutrients and multiple altered species	Johannes R. Hov	Received

SAT-117	Hemodynamic effects of direct-acting antivirals in patients with hepatitis-C virus-associated cirrhosis and portal hypertension non responsive to beta-blockers	Edilmar Alvarado	Received

THU-118	Obeticholic acid but not bezafibrate treatment improves cholestasis-induced cognitive decline	Lucy Gee	Received

SAT-118	Improving nutritional care in patients with liver cirrhosis: a quality improvement project	Syazeddy Samani	Received

FRI-118	Long-term safety profile of cenicriviroc in adults with non-alcoholic steatohepatitis: rollover study	Sven Francque	Received

SAT-119	90-day mortality is lower after as compared to before transjugular intrahepatic portosystemic shunt at the same model for end-stage liver disease score	Laurie Eicher	Received

FRI-119	Novel autophagy inducer, a4368 improves non-alchoholic steatohepatitis in mice	Hyun Jin Jung	Received

THU-119	Negative immune regulator LNK/SH2B3 contributes to the development of autoimmune liver disease in mice under fatty-metabolic stress	Taizo Mori	Received

THU-120	Mast cell activation mediates biliary immunobiology and subsequent immune response in a model of primary biliary cholangitis	lindsey kennedy	Received

SAT-120	Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis	Alessandra Pivetti	Received

FRI-120	Intrahepatic microcirculation disorders and increased blood ammonia at the chronic liver diseases with initial stage of liver fibrosis	Tatiana Ermolova	Received

FRI-121	Composite targeting of nuclear receptors protects against diet-induced NAFLD	Tawhidul Islam	Received

FRI-122	Patient-reported benefits for future non-alcoholic steatohepatitis therapy: a global real-world study among 1,035 patients across 12 countries	Victoria Higgins	Received

THU-122	Klebsiella in the mucosal gut microbiota in primary sclerosing cholangitis is associated with more severe disease	Mikal Jacob Hole	Received

THU-123	Downregulation of the bile acid receptor TGR5 in livers of PSC patients and ABCB4-/- mice	Maria Reich	Received

SAT-123	The diagnosis of sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis	Nicoletta Fabrini	Received

SAT-124	Interest of echocardiography in the management of acute kidney injury in cirrhotic patients with ascites. Results of the prospective pilot cirren study	Fanny Lebossé	Received

THU-124	Insufficient deletion of autoreactive CD4 T cells and plasticity of Tregs drive spontaneous autoimmune hepatitis in mice	Max Preti	Received

FRI-124	Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on the alkaline phosphatase	Alessio Gerussi	Received

FRI-125	Ursodeoxycholic acid and/or ciprofibrate for treating patients with presumptive diagnosis of low phospholipid cholelithiasis, a clinical spectrum of progressive familial intrahepatic cholestasis type 3	Ana Cardoso	Received

THU-126	Co-stimulatory molecules OX40 and CD30 mediates the regeneration of the liver epithelium in a mouse primary scletosing cholangitis model	Naruhiro Kimura	Received

SAT-126	Head to head comparison of liver stiffness measurement using transient elastography, 2D-shear wave elastography and magnetic resonance elastography for non-invasive evaluation of clinical significant portal hypertension	Filipe Andrade	Received

FRI-126	Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients	Anna Reig	Received

SAT-127	A hypercoagulable state does not play a major role in the development of portal vein thrombosis in patients with cirrhosis	Fanny Turon	Received

FRI-127	Histological features of non-alcoholic steatohepatitis are common in patients with autoimmune hepatitis who have advanced fibrosis at diagnosis	Michael Patrick Johnston	Received

FRI-128	Histological primary biliary cholangitis changes in patients with positive serology and normal alkaline phosphatase	Benedetta Terziroli	Received

SAT-128	Comparison of the diagnostic quality of aspiration and core biopsy needles for transjugular liver biopsy	Georg Semmler	Received

THU-128	Relevance of epidermal growth factor receptor kinase activity in a model of cholestatic liver injury	Nerea Lazcanoiturburu	Received

THU-129	The role of cellular senescence in the natural course of primary sclerosing cholangitis	Nora Cazzagon	Received

THU-130	Upregulation of hepatic TH17 response is associated with large duct disease and advanced hepatic fibrosis in pediatric autoimmune liver disease	Simon Lam	Received

SAT-130	Ammonia is an independent biomarker of poor outcomes in patients with advanced cirrhosis	Gonalo Alexandrino	Received

SAT-131	Survival outcomes of SBP, BA and CNNA in a large Scottish cohort	Malgorzata Grzelka	Received

FRI-131	Psychometric evaluation of the adult itch reported outcome tool, a worst-itch numeric rating scale in adults with cholestatic liver disease	Brandon Foster	Received

THU-132	Single cell RNA sequencing reveals naive T cells ready for effector function in livers of patients with primary sclerosing cholangitis	Tobias Poch	Received

SAT-132	Risk stratification and the effects of early tips among patients with Child-Pugh B cirrhosis and acute variceal bleeding	Guohong Han	Received

FRI-132	Effectiveness of obeticholic acid (OCA) in southern European patients with primary biliary cholangitis (PBC) as a second line therapy. A multicenter, international, real- world cohort	Conrado Fernandez-Rodriguez	Received

THU-133	Integrated analysis of GWAS and mRNA microarray identified IFN-? and CD40I as the central upstream-regulators in primary biliary cholangitis	Kazuko Ueno	Received

FRI-133	Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study	Mary Standen	Received

SAT-133	Risk factors for sarcopenia and its impacts on clinical outcome in patients with liver cirrhosis	Huijuan Xiao	Received

THU-134	FcRL4 b cells are associated with inflamed bile ducts in patients with primary biliary cholangitis and locally capture IGA immune complexes	Yuxin Liu	Received

FRI-134	Hepatocellular carcinoma in patients with autoimmune hepatitis: prevalence and risk factors	Nayana Vaz	Received

SAT-134	The burden of cirrhosis on the Canadian healthcare system: a comparison between alcoholic and non-alcoholic cirrhosis patients	Hassan Azhari	Received

THU-135	Bile from patients with chronic liver diseases activates MAIT cells	Fei Zheng	Received

THU-136	Inhibition of toll-like receptor 4 signaling reduces hyperammonemia by modulating urea cycle function	Annarein Kerbert	Received

SAT-136	Collagen type XVIII is associated with platelet count and meld score in patients with trans-jugular intrahepatic portosystemic shunt	Ida Villesen	Received

THU-137	Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis	Alberto Zanetto	Received

SAT-137	Terlipressin vs noradrenaline for the treatment of hepatorenal syndrome in patients with acute-on-chronic liver failure: a 5-year retrospective analysis	Ilaria Giovo	Received

SAT-138	Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites	Ioannis Petridis	Received

FRI-138	Poor diagnostic accuracy of blood igG4/igG RNA ratio for discriminating igG4-related disease from pancreatic or biliary cancer (DIPAC ): a prospective cohort study	Elsemieke de Vries	Received

THU-138	Different inflammasome activation predisposes for acute-on-chronic liver failure depending on hepatic compensation in human and experimental liver cirrhosis	Sofia Monteiro	Received

FRI-139	Glucuronidation directs systemically available norursodeoxcholic acid (norUDCA) to the kidney	Michael Stie	Received

SAT-139	Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial	Penelope Markham	Received

THU-139	Impaired splenic function in liver cirrhosis: a study in 69 patients with cirrhosis from outpatient hepatology clinic in a tertiary hospital in northern Greece	Lamprini Kirkineska	Received

THU-140	Histological characterization of muscle and adipose tissue in patients with cirrhosis receiving liver transplant	Maryam Ebadi	Received

FRI-140	Predictive factors of response to corticosteroid therapy in acute severe autoinmune hepatitis: a national multicentric study	Eugenia Sánchez Rodríguez	Received

FRI-141	Antibodies against glycoprotein 2 and anti-neutrophil cytoplasmic antibodies targeting the serine proteinase 3 are markers of severe primary sclerosing cholangitis (PSC) and progression to cholangiocarcinoma (CCA)	Ewa Wunsch	Received

THU-141	A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrotic patients treated with direct-acting antivirals	Elisabetta Degasperi	Received

THU-142	The bone marrow pool of megakaryocytes and their ability to proliferate are preserved in rats with advanced cirrhosis	Iris Asensio	Received

FRI-142	Analysis of 1,776 patients with primary sclerosing cholangitis from a laboratory database	Friedrich Mittermayer	Received

SAT-142	Lactulose withdrawal can potentiate breakthrough overt hepatic encephalopathy in patients controlled with rifaximin plus lactulose therapy: a post hoc analysis of a randomized controlled trial	Katie Rogers	Received

SAT-143	Microbiome metabolic therapies reduce microbiota-associated ammonia in ex vivo fecal samples from healthy subjects and patients with minimal hepatic encephalopathy and demonstrate improved tolerability over lactulose in a clinical study	Robin Raskin	Received

THU-143	Bile acids modify ROS production, impair chemotaxis and delay apoptosis of neutrophils in vitro	Irina Komarova	Received

SAT-144	KB174 reduces relative abundance of multidrug resistance (MDR) enterobacteriaceae in fecal samples from patients with cirrhosis in an ex vivo test system	Robin Raskin	Received

FRI-144	Risks and benefits of percutaneous transhepatic cholangiodrainage in patients with primary sclerosing cholangitis	Gustav Buescher	Received

SAT-145	Prevalence and clinical significance of portal vein thrombosis in cirrhotic patients with acute decompensation	Yan Zhang	Received

FRI-145	Antimitochondrial antibodies in patients with autoimmune hepatitis: a large multicenter study	Nikolaos Gatselis	Received

SAT-146	Pre-emptive (early) transjugular intrahepatic porto-systemic shunt in the treatment of high-risk acute variceal bleeding. An individual patient data meta-analysis	Oana Nicoara Farcau	Received

THU-146	SLU7 downregulation potentiates liver damage through hepatic de-differentiation	María Gárate-Rascón	Received

FRI-146	Durability of biochemical improvements through six years of open label treatment with obeticholic acid in patients with primary biliary cholangitis who did not achieve the poise criteria	Sari Rizk	Received

SAT-147	Increased risk of perinatal complications in women with cirrhosis: a population-based matched cohort study	Jennifer Flemming	Received

THU-147	Endotrophin predicts clinical outcome and mortality in patients with compensated cirrhosis	Mette Juul Nielsen	Received

FRI-147	Enhanced liver fibrosis test and liver stiffness variation over time in a prospective cohort of primary sclerosing cholangitis patients	Guri Fossdal	Received

THU-148	Characterization of lymphocyte subsets in ascites during spontaneous bacterial peritonitis: MAIT cells show the strongest increase	Christian Niehaus	Received

SAT-148	Does the wedge hepatic vein pressure estimates the portal pressure in patients with NASH cirrhosis?	José Ferrusquía-Acosta	Received

FRI-148	An international perspective on cholestatic pruritus in primary biliary cholangitis (PBC)	Helen Smith	Received

THU-149	Immune cell response in progressing liver cirrhosis is dominated by neutrophil granulocytes	Rhea Veelken	Received

FRI-149	Magnetic resonance imaging features of primary biliary cholangitis	Ilkay Idilman	Received

SAT-150	Prediction of variceal eradication in decompensated liver cirrhosis: a novel model	Xing Wang	Received

THU-150	Proagio: a protein designed to target integrin alpha V beta 3 outside ligand binding site is an effective way to target activated hepatic stellate cells	Ravi Chakra Turaga	Received

FRI-150	Comparison of liver stiffness measurement with MRE and liver and spleen volumetry for prediction of disease severity and hepatic decompensation in patients with primary sclerosing cholangitis	Ilkay S. Idilman	Received

FRI-151	The inter-relationship between primary sclerosing cholangitis and socioeconomic status	Jessica Dyson	Received

SAT-151	A comparison of non-invasive methods for the screening of gastroesophageal varices in patients with compensated cirrhosis	Jonathan Ng	Received

THU-151	Hepatocytes undergo pyroptosis in response to lipopolysaccharide exposure, and can be sensitised to cell death by ER stress	Ugo Soffientini	Received

THU-152	Faecal cytokines provide novel insights into the role of gut mucosal inflammation in acute decompensation of cirrhosis	Vishal C Patel	Received

SAT-152	Pre-procedural blood product transfusion and bleeding predictors in patients with chronic liver disease undergoing elective invasive procedures at a tertiary liver unit	Jonathan Durbin	Received

FRI-152	Change in risk of primary biliary cholangitis is associated with the evolution of coal mining	Jessica Dyson	Received

SAT-153	Urinary liver fatty-acid binding protein (UL-FABP) predicts acute-on-chronic liver failure (ACLF) and mortality in patients with decompensated cirrhosis	Adrià Juanola	Received

FRI-154	The clinical significance of programmed cell death-1 rs11568821 and interleukin-28b rs12979860 polymorphisms in autommune hepatitis	Kalliopi Azariadi	Received

SAT-154	Sarcopenia and liver cirrhosis: comparison of the European working group on sarcopenia criteria 2010 and 2019	Julia Traub	Received

SAT-155	Validation of diagnostic usefulness of the spot urine Na/K ratio for replacement of 24-hour urine NA excretion in cirrhotic patients with ascites	Jinwook Lee	Received

FRI-155	Histological characteristics of primary biliary cholangitis with an incomplete response to ursodeoxycholic acid	Kenichi Harada	Received

THU-156	The role of urea on the prognosis of severe acute liver injury and acute liver failure	Ana Craciun	Received

FRI-156	Maternal and foetal outcomes, biochemistry and immunology changes during pregnancy in patients with autoimmune hepatitis	Kathryn Olsen	Received

SAT-156	Proton pump inhibitor use is associated with an increased risk of hepatic encephalopathy in a large cohort of patients with cirrhosis	Koos de Wit	Received

THU-157	Idiosyncratic drug-induced liver injury in the elderly: an analysis of cases from the Spanish DILI registry	Raul J. Andrade	Received

FRI-157	Impaired sulfation capacity may deteriorate clinical course in patients with primary sclerosing cholangitis (PSC)	Karolina Maria Wronka	Received

SAT-157	Quality improvement campaign led to higher surveillance rate for hepatocellular carcinoma in primary care clinic	Kanit bunnag	Received

THU-158	Use of the molecular adsorbent recirculating system in acute liver failure: a North American multicenter experience	Andrew MacDonald	Received

SAT-158	Calf circumference as an easy surrogate marker for the screening of Japanese patients with chronic liver disease	Kei Endo	Received

FRI-158	Accuracy of liver stiffness measurement in assessing liver fibrosis in naive patients with primary biliary cholangitis	Laura Cristoferi	Received

THU-159	MELD score is the best predictor for transplant-free survival in patients with acute liver injury	Carolina Simes	Received

FRI-159	Ciprofibrate: a new option of fibrate for primary biliary cholangitis with incomplete response to ursodeoxycholic acid	Laura Guedes	Received

SAT-159	A novel method: can stapedial acoustic reflex have a role in the diagnosis of minimally hepatic encephalopathy?	Bugra Tolga Konduk	Received

THU-160	Ketamine for maintenance sedation in critically ill burned patients is associated with liver dysfunction and acute kidney injury	Christian de TYMOWSKI	Received

SAT-160	Real-world treatment patterns and outcomes in hepatorenal syndrome: results from a retrospective chart review study in the United Kingdom	Shelby Corman	Received

FRI-160	Utility of thiopurine metabolite testing in autoimmune hepatitis: defining an optimal therapeutic range for disease management and measurement may avert relapse and adverse drug reactions	Lena Candels	Received

SAT-161	Validation of HCC risk calculator in a UK centre and implications of thresholds for screening	Laura Atkins	Received

FRI-161	Correlation of serum bile acids and pruritus with aldafermin (NGM282) therapy in patients with primary sclerosing cholangitis	Lei Ling	Received

THU-161	The therapeutic role of iNOS-expressed myeloid derived suppressor cells in acetaminophen induced acute liver failure	Chien-Hao Huang	Received

SAT-162	Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease in patients with portal hypertension	Laure Elkrief	Received

SAT-163	The utilisation of palliative care in patients with end-stage liver disease	Lauren Andersson	Received

FRI-163	Development and validation of a novel risk score predicting long -term survival in autoimmune hepatitis	Maaike Biewenga	Received

THU-164	Ferroptosis related regulatory protein NCOA4 and its lncRNA-mRNA co-expression network in patients witn anti-tuberculosis drug-induced liver injury	Jun Chen	Received

THU-165	AARC score has better accuracy at predicting 90-day mortality in drug induced acute-on-chronic liver failure (DILI - ACLF )	Sushrut Singh	Received

SAT-165	Continuous infusion of terlipressin for hepatorenal syndrome therapy: evaluation of efficacy and safety in real-life setting	Fernanda S. Linhares	Received

FRI-165	Understanding of central and peripheral fatigue in primary biliary cholangitis	Naw April Phaw	Received

SAT-166	Frailty assessed by the liver frailty index (LFI) predicts poor health-related quality of life (QOL) in patients hospitalised with liver cirrhosis	Lubomir Skladany	Received

FRI-166	Genetic variant c.711 in the hepatobiliary phospholipid transporter ABCB4 is associated with clinically relevant liver stiffness in chronic liver diseases	Marcin Krawczyk	Received

SAT-167	A novel score to predict mortality after transjugular intrahepatic portosystemic shunt in patients with renal insufficiency	Luisa Fuerschu	Received

FRI-167	Response to treatment in autoimmune hepatitis determines the health-related quality of life	Maurice Michel	Received

SAT-168	Differential activation of humoral compensatory mechanisms in distinct stages of portal hypertension	Lukas Hartl	Received

FRI-168	Serum bile acid species are associated with liver fibrosis and clinical disease progression in patients with primary sclerosing cholangitis	Jun Xu	Received

THU-168	Novel in vivo tracing of the hepatocyte origin of extracellular vesicles in mice with experimental liver disease	Elena Blázquez-López	Received

SAT-169	Prospective study of magnetic resonance spectroscopy identifies specific metabolic changes in covert hepatic encephalopathy	Nway Yadanar Tun	Received

FRI-169	Removal of fibrosis-related genes identifies a hepatic gene expression signature that identifies canonical signaling pathways and is correlated with clinical outcomes in patients with primary sclerosing cholangitis	Chuhan Chung	Received

FRI-170	Hepatic transcriptomic analysis identifies a mast cell gene expression signature that correlates with fibrosis stage and is prognostic in patients with primary sclerosing cholangitis	Chuhan Chung	Received

THU-170	Activation ot the aryl hydrocarbon receptor sensitizes to acetaminophen-induced acute liver failure	Fenja Schuran	Received

SAT-170	Bacterial infections correlate with poor prognosis in cirrhosis independently from liver disease severity	Maria Corina Plaz Torres	Received

FRI-171	Simultaneous liver and spleen stiffness measurements as complementary methods for fibrosis quantification in autoimmune hepatitis	Maciej Janik	Received

THU-171	Human bone marrow mesenchymal stem cells small extract vesicles promote hepatocyte regeneration in acute liver failure	Juan Gao	Received

THU-172	Cut-off level of serum cytokeratin 18 for diagnosis of acute-on-chronic liver failure in chronic hepatitis C cirrhosis	Hany Shabana	Received

THU-173	Air-liquid interactive bioartificial liver embedded with 3D-layered human hepatocyte-derived liver progenitor-like cells rescues pocine acute liver failure	Hexin Yan	Received

SAT-173	Value of Hitachi shear wave elastography (SWE) for exclusion of esophageal varices in patients with compensated advanced liver disease	Marcel Razpotnik	Received

FRI-173	Machine learning models accurately interpret liver histology and are associated with disease progression in patients with primary sclerosing cholangitis	Vicki Mountain	Received

SAT-174	Factors associated with the presence of cirrhotic cardiomyopathy defined according to the new multidisciplinary diagnostic criteria	Marcel Razpotnik	Received

THU-174	Outcomes following deceased and live donor liver transplantation for the indication of acute liver failure: a multicenter experience	Ilker Turan	Received

FRI-174	CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2-/- mouse model.	Arnon Aharon	Received

SAT-175	Prevalence of cirrhotic cardiomyopathy according to the old and new diagnostic criteria	Marcel Razpotnik	Received

THU-175	Expression of microRNA-124 in Kupffer cells modulates liver injury	Jinyu Wang	Received

FRI-175	Belimumab: a promising third line treatment option for refractory autoimmune hepatitis	Pinelopi Arvaniti	Received

FRI-176	European Association for the Study of the Liver primary biliary cholangitis guideline clinical care standards: the patient experience as recorded by PBC Foundation app and International Patient Registry	Robert Mitchell-Thain	Received

SAT-176	Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection	Marco Senzolo	Received

THU-176	Predictors of acute liver failure and death among patients with dengue-induced severe hepatitis	Tongluk Teerasarntipan	Received

THU-177	Clinical and radiological features for early identification of malignancy induced acute liver failure	Liane Rabinowich	Received

FRI-177	A multi-disciplinary approach to igG4 related disease aids in diagnosis and management	Rory Peters	Received

SAT-177	Reduced efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis over time: a systematic review and meta-analysis	Marcus Mcke	Received

FRI-178	Long-term prevalence of gastro-oesophageal varices in early primary biliary cholangitis patients with good response to treatment	Toru Setsu	Received

SAT-178	Risk assessment of clinically significant portal hypertension by means of hepatosplenic volumetry in compensated cirrhosis	mario romero cristóbal	Received

THU-178	Deletion of XBP1 in liver parenchymal cells ameliorates acetaminophen (APAP)-induced hepatotoxicity via activation of IRE1alpha-JNK1-ATG5-dependent autophagy	Hui Ye	Received

SAT-179	Zinc deficiency in cirrhosis predicts hepatic decompensation and mortality	Marta Hernández Conde	Received

FRI-179	Symptom burden in patients living with primary biliary cholangitis: indigenous Canadians report significantly higher PBC-40 quality of life scores	Surain Roberts	Received

SAT-180	A nomogram as an indirect method to identify sarcopenia in patients with liver cirrhosis	Marta Hernández Conde	Received

FRI-180	Efficacy and tolerance of obeticholic acid in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid in real life: interim analysis of the OCARELIFE study	Sari Rizk	Received

THU-180	The protective effects of a sense oligonucleotide drug targeting inducible nitric oxide synthase for a rat model of acute liver injury	Richi Nakatake	Received

SAT-181	Impact of beta blocker therapy on systemic inflammation stratified by hepatic venous pressure gradient response	Mathias Jachs	Received

THU-181	Hasi-iquest: investigating viral etiologies of acute liver failure of unknown cause	Nicolas Gille	Received

FRI-181	Lost in the system: identification of patients with undiagnosed primary biliary cholangitis	Jorge Yebra Carmona	Received

SAT-182	Protective effects of statin therapy in liver cirrhosis are limited by the common SLCO1B1 variant	Melissa Merkel	Received

FRI-183	Mesenchymal stem cells regulated DX5 - liver natural killer cells in rescuing acute-on-chronic liver failure murine	Jing Xiong	Received

SAT-183	Shifting the focus of liver cirrhosis to prevention with the help of the SEAL program	Michael Nagel	Received

THU-183	Investigation into the cut-off point for chronicity of drug-induced liver injury through metabolomic profiling	Jia-bo Wang	Received

FRI-184	Selecting patients with decompensated cirrhosis and acute-on-chronic liver failure (ACLF) admitted to the intensive care unit for liver transplantation	Sophie-Caroline Sacleux	Received

THU-184	Hepatic steatosis predicts fibrosis in long-term methotrexate use	Marcel Tomaszewski	Received

SAT-184	Algorithm to predict development of sarcopenia after transjugular intrahepatic portosystemic shunt in decompensated cirrhosis	Michael Praktiknjo	Received

FRI-185	Improving the survival rate of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis	Danli Chen	Received

SAT-185	In-hospital falls and fall-related injury in patients with liver-cirrhosis - malnutrition matters	Nada Abedin	Received

THU-185	Novel therapy with anti-miR-873-5p at late stages of acetaminophen overdose	Rubén Rodríguez Agudo	Received

FRI-186	Soluble immune checkpoints are involved in the immunopathogenesis of ACLF	Douglas Corrigall	Received

SAT-186	Body composition parameters predict outcomes of acute kidney injury in patients with cirrhosis	Naomi Lange	Received

THU-186	A novel HER2-targeted liposomal formulation for reducing the risk of liposome-induced hepatotoxicity	Sara De Martin	Received

THU-187	Combination of sivelestat and n-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury	Sarah Raevens	Received

SAT-187	Usefulness of handgrip as a non-invasive tool to predict the outcome of patients with cirrhosis. A prospective study	Nesrine AMARI	Received

FRI-188	Differential hepatic mRNA and miRNA expression patterns in a novel mouse model of bacterial infection related to acute-on-chronic liver injury	Ersin Karatayli	Received

THU-188	GSDMD inhibitor necrosulfonamide protects mice from galactosamine/lipopolysaccharide-induced acute liver failure via pyrotosis pathway	Yi-Long Wu	Received

FRI-189	The prevalence of multi-resistant bacterial infections in patients with decompensated cirrhosis admitted to the intensive care unit	Fischer Petra	Received

THU-189	Administration of lactobacillus alleviates experimental NASH by reducing miR-21 in the liver	André A. Santos	Received

SAT-189	Factor VIII/protein C and not ADAMTS13/VWF:Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score	Niccolò Bitto	Received

FRI-190	Acute-on-chronic liver failure as defined by the European (EASL-CLIF) versus North American (NACSELD) diagnostic criteria in their prediction of short-term prognosis in patients with decompensated cirrhosis admitted into hospital	Florence Wong	Received

THU-190	Disease severity and proton pump inhibitor use impacts strongest on faecal microbiome composition in cirrhosis	Angela Horvath	Received

SAT-190	Baveno VI criteria as a prognosis index for clinical complications in patients with cirrhosis	Nicolas Asesio	Received

SAT-191	Systemic and splanchnic hemodynamic features of patients with porto-sinusoidal disease as compared with cirrhosis	Nicolas Drilhon	Received

FRI-191	Novel experimental animal models for acute decompensation and acute-on-chronic liver failure	Frank Erhard Uschner	Received

SAT-192	Circulating microfibrillar-associated protein 4 is an independent predictor of transplant-free survival in compensated and decompensated cirrhosis	Nikolaj Torp	Received

FRI-192	Artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure patients	Qian Zhang	Received

SAT-193	Tunnelated peritoneal catheter versus large volume paracentesis for refractory ascites in cirrhosis: a randomized controlled trial	Nina Kimer	Received

THU-193	Gut microbiota and metabolites associated with response to ursodesoxycholic acid in patients with primary biliary cholangitis	Bin Gao	Received

THU-195	Microbiota modulates ischemia-reperfusion injury in mouse liver transplantation	Shoichi Kageyama	Received

FRI-195	Refining the renal failure criteria of the EASL-CLIF diagnostic model for defining acute- on- chronic liver failure (ACLF)	Joana Calvão	Received

SAT-196	Efficacy of transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease	Paola Ponzo	Received

FRI-196	Regulation of IL-22 in a rat model for acute-on-chronic liver failure (ACLF)	Katharina Maria Schwarzkopf	Received

THU-197	Transplantation of gut microbiota derived from MCJ-KO genotype determines a protective profile against non-alcoholic fatty liver disease in germ-free mice	David Porras	Received

SAT-197	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI	Paul Cales	Received

FRI-197	Thymosin alpha 1 for patients with hepatitis B virus-related acute-on-chronic liver falure: a randomized controlled trial	Jun-feng Chen	Received

THU-198	Effects of anti-TNF? treatment on Crohns disease induced hepatic steatosis	Paul Manka	Received

FRI-198	Derivation and validation of prognostic nomogram for HBV-related acute-on-chronic liver failure	Jun-feng Chen	Received

SAT-198	Direct acting oral anticoagulant use in cirrhosis patients: real-world bleeding and discontinuation rates	Patrick Northup	Received

THU-199	Investigation of microbiome metabolites and mitochondrial function in non-alcoholic fatty liver disease	Paula Boeira	Received

SAT-199	Fluency is associated with hepatic encephalopathy using a common and easy language task	Patricia Bloom	Received

THU-200	Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for aldafermin (NGM282) in patients with non-alcoholic steatohepatitis	Rohit Loomba	Received

SAT-200	A smartphone app is feasible for outpatient ascites management	Patricia Bloom	Received

FRI-200	Mesenchymal stem cells regulate hepatocytes excessive autophagy and apoptosis through miR-125b/TRAF6 pathway in acute- on- chronic liver failure	Dengna Lin	Received

SAT-201	Comparative study between spontaneous fungal peritonitis and spontaneous bacterial peritonitis in patients with end stage liver disease	Mohamed Elnadry	Received

SAT-202	Association between proton pump inhibitor use in hospitalized cirrhotics and development of hepatic encephalopathy and spontaneous bacterial peritonitis	Pearl Tan	Received

SAT-203	Sarcopenia increases the risk of post transjuglar intrahepatic portosystemic shunt hepatic encephalopathy	Puja Bhatia Kapoor	Received

FRI-204	Different transcriptome characteristics of peripheral blood mononuclear cells are associated with survival outcome in hepatitis B-related acute-on-chronic liver failure	Shanshan Ma	Received

SAT-204	Distinct features of the portalhypertensive syndrome in patients with advanced chronic liver disease due to non-alcoholic steatohepatitis	Rafael Paternostro	Received

THU-204	Identification of gut bacterial candidates involved in hepatic encephalopathy by the analysis of feces DNA from patients administered rifaximin	Yoshimi Muto	Received

SAT-205	A novel, smartphone-based scleral image capture technique accurately determines serum bilirubin level and can be used for home-based monitoring of patients discharged from hospital, after an episode of acute decompensation	Katarina Gluic	Received

FRI-205	Granulocyte colony-stimulating factor in acute-on-chronic liver failure: systematic review and meta-analysis	Rosa Martin- Mateos	Received

THU-206	Hepatocyte-targeted R-spondin mimetic for liver regeneration	HELENE BARIBAULT	Received

FRI-206	Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells	Sabrina Rueschenbaum	Received

SAT-207	Long-term 20 albumin administration normalizes the plasma albumin binding capacity in patients with decompensated cirrhosis	Raquel Horrillo	Received

THU-207	Primed liver regeneration in protein convertase subtilisin/kexin type 9 knockout mice is associated with increased lipids uptake and hypercholesterolemia	Jacopo Gavini	Received

SAT-208	Aminoglycosides and metronidazole for the treatment of hepatic encephalopathy in adults with cirrhosis	Rebecca Jeyaraj	Received

THU-208	Targeting the embryonic liver with ultrasound-guided in utero nano-injection to manipulate gene expression during liver development and hematopoiesis	Jingyan He	Received

FRI-208	Serum cholinesterase, an underestimated marker in the prediction of acute-on-chronic liver failure, organ failure and LTx -free survival in patients with liver cirrhosis?	Tammo Lambert Tergast	Received

SAT-209	Spleen stiffness and liver stiffness for predicting high risk varices in patients with compensated liver cirrhosis	Renata Fofiu	Received

THU-210	Dynamic characterization of revascularization in decellularized whole-liver scaffold	Jun Li	Received

FRI-210	Single- centre experience of implementing a hepatology outreach service to improve patient care for emergency admissions of acutely decompensated cirrhosis	Tomi Ashaye	Received

SAT-210	Natural history and outcomes of patients with liver cirrhosis complicated by hepatic hydrothorax	Sarah Romero	Received

THU-211	Optimal liver metabolism and proliferation require the tight junction protein claudin-3	Felix Alexander Baier	Received

SAT-211	Acute or recent portal vein thrombosis in cirrhosis predicts a hidden or upcoming diagnosis of hepatocellular carcinoma	Rifaat Safadi	Received

FRI-212	Clinical features and natural history of acute-on-chronic liver failure precipitated by any indeterminate factor: single-center observational study	Hitomi Hoshi	Received

THU-213	Serum transferrin levels reflect hepatocyte nuclear factor 4 alpha activity in the liver	Nurdan Gldiken	Received

SAT-213	A prospective evaluation of the Bristol prognostic score: poor sensitivity and specificity in a non-Bristol cohort	Sarah Bowers	Received

FRI-214	Baseline demographics and clinical characteristics of subjects enrolled in the phase 3 AURORA study of cenicriviroc for the treatment of liver fibrosis associated with non-alcoholic steatohepatitis	Naim Alkhouri	Received

SAT-214	Blood and ascites pharmacokinetics of meropenem in patients with nosocomial spontaneous bacterial peritonitis and decompensated liver cirrhosis	Marie Schultalbers	Received

THU-214	Macrophage regulation of PKM2 during liver regeneration process	Melin Nicolas	Received

SAT-215	Diagnostic performance of contrast-enhanced CT for the diagnosis of portosinusoidal vascular disease: a case-control study	Shantha Valainathan	Received

FRI-215	Diagnostic accuracy of a pocket-size ultrasound device in identifying liver surface nodularity for fibrosis staging in chronic liver disease	Andrea Costantino	Received

THU-216	Diploid hepatocytes drive physiological liver renewal in adult humans	Olaf Bergmann	Received

FRI-216	Combination of an acetyl CoA carboxylase inhibitor with therapeutics that promote fatty acid oxidation moderately improves efficacy in a preclinical NASH model	ARCHANA VIJAYAKUMAR	Received

THU-217	Imaging human liver regeneration by multiphoton microscopy	Scott Davies	Received

SAT-217	A nurse-led albumin infusion service reduces the need for therapeutic paracentesis in the outpatient day procedure setting	Siddharth Sood	Received

SAT-218	Increased levels of soluble mannose receptor are associated with poor outcome in cirrhosis: results from a 2-year longitudinal study	Signe Wiese	Received

SAT-219	MRI-derived myocardial extracellular volume is closely associated with markers of collagen formation in cirrhosis	Signe Wiese	Received

SAT-220	FIB-4 and APRI-scores predict survival in patients with transjugular intrahepatic portosystemic stent shunts	Antoaneta Angelova Markova	Received

THU-220	Potential role of two novel agonists of thyroid hormone receptor-beta on liver regeneration	Simona Onali	Received

SAT-221	Real-world effectiveness of piperacillin/tazobactam-based therapies for spontaneous bacterial peritonitis	Stefanie Quickert	Received

THU-221	Parenchyma-sparing hepatectomy improves salvageability and survival for solitary small intrahepatic cholangiocarcinoma	Hui Li	Received

FRI-222	Enigma proteins control YAP1 related mechano-transduction in hepatic stellate cells	Dina Abdelmottaleb	Received

SAT-222	Etiology and diagnosis of ascites: contemporary cohort study in a secondary care setting	Mohsan Subhani	Received

THU-222	Reducing length of stay in patients following a liver transplant	Abdulrhman Alamr	Received

SAT-223	Sarcopenia is not associated with poor outcomes after transjugular intrahepatic portosystemic shunt insertion for refractory ascites	Thomas Tranah	Received

THU-223	The presence and outcome of biliary sphincter disorders in liver transplant recipients according to the Rome IV classification	Andres Cardenas	Received

THU-224	Impact of sarcopenia in patients awaiting simultaneous liver and kidney transplantation: a cohort of study on clinical outcomes	Alessandra Mazzola	Received

SAT-224	Impact of acute decompensation on prognosis in patients with hepatocellular carcinoma	Takayuki Kondo	Received

FRI-224	The IL-17a and IL-22 cytokines like triggers of human liver fibrosis	Daria Kartasheva-Ebertz	Received

FRI-225	Fib-4 score for assessment of liver fibrosis is useful in general practice	Denis Ouzan	Received

SAT-225	Serum cholinesterase is an independent predictor of hepatic encephalopathy, acute-on-chronic liver failure and mortality after transjugular intrahepatic portosystemic shunt insertion in patients with liver cirrhosis	Lena Thle	Received

FRI-226	Analysis of PNPLA3 SNP variants in human hepatic stellate cells in 3D human liver extracellular matrix scaffolds reveals key PNPLA3-dependent pro-fibrogenic features	Elisabetta Caon	Received

SAT-226	Transjugular intrahepatic portosystemic shunt in cirrhotic elderly patients with refractory ascites - to do or not to do?	Lena Thle	Received

THU-227	A new score including anthropometric measurement for weight improved prediction of mortality in adolescents on the liver transplantation waiting list: a US nationwide study	Abdel Aziz Shaheen	Received

SAT-227	Four weeks of aerobic and resistance training improves frailty in patients with liver cirrhosis-liver habilitation (Li-Hab) center outcome data	Varsha Shasthry	Received

FRI-227	An HSV-TK / valganciclovir mouse model enables the study of fibrocytes in liver fibrosis	Felix Hempel	Received

THU-228	Post-transplant lymphoproliferative disease after adult liver transplantation has a higher incidence after primary sclerosing cholangitis and can be prevented by surveillance of Epstein-Barr viral load with a pre-emptive strategy - a long-term study	Bastian Ruijter	Received

SAT-228	Effect of rivaroxaban on hypercoagulopathy risk factors in liver cirrhosis patients with nonvalvular atrial fibrillation	Nataliya Virstyuk	Received

THU-229	De novo metabolic syndrome after liver transplantation: a prospective, longitudinal study	Chiara Becchetti	Received

SAT-229	Between rapid diagnosis and prediction of survival in minimal hepatic encephalopathy	Vlad Taru	Received

FRI-230	TGF-beta3 plays a prominent role in murine parenchymal liver fibrosis	Hiroyuki Abe	Received

THU-230	Phase angle is a prognostic nutritional marker in patients on the waiting list and after liver transplantation	Berenice M. Román-Calleja	Received

SAT-230	Efficacy and safety of rivaroxaban in portal vein thrombosis in patients with liver decompensated cirrhosis	Min Wang	Received

FRI-231	MUDENG (mu-2 related death-inducing gene) overexpression accelerates liver fibrosis in carbon tetrachloride-induced cirrhosis	Ju-Yeon Cho	Received

SAT-231	Test-retest reliability of hepatic venous pressure gradient: a study in 215 patients from the control arms of 17 randomized controlled trials	Wayne Bai	Received

FRI-232	Thrombofibrosis: inherited thrombophilia as a cause of significant liver fibrosis	Iranzu Ezcurra	Received

FRI-234	An improved method for liver fibrosis assessment using magnetic resonance elastography	JunSheng, Jaryl Cheng	Received

THU-234	Severe obesity increases death and dropout from liver waiting list: French liver transplant cohort	Claire Delacte	Received

SAT-234	Empirical carbapenem versus third-generation cephalosporin treatment for spontaneous bacterial peritonitis: a multicenter study	Sun Woong Kim	Received

FRI-235	Expression of cyclin E1 and CDK2 in hepatic stellate cells is critical for initiation and progression of liver fibrosis in mice	Julia Hennings	Received

SAT-235	Early albumin improves survival in cirrhotic patients on diuretic therapy who develop significant acute kidney injury: real-world evidence in the United States	Santosh Telang	Received

THU-236	Liver transplantation assessment: what are the factors associated with contraindication for listing or delayed activation on waiting list?	Domitille Erard-Poinsot	Received

FRI-236	Non-canonical autophagy in myeloid cells constrains hepatic and systemic inflammation and limits fibrosis	JingHong Wan	Received

SAT-236	Test-retest reliability of hepatic venous pressure gradient: a study in 215 patients from the control arms of 17 randomised controlled trials	Wayne Bai	Received

THU-237	Anticoagulation in liver transplant candidates: a case control study	Domitille Erard-Poinsot	Received

FRI-237	Reduction in types I and III collagen gene expression by an alphavbeta1 integrin inhibitor correlates with a decrease in PRO-C1 and PRO-C3 levels in precision-cut liver tissue slices from cirrhotic non-alcoholic steatohepatitis patients	Johanna Schaub	Received

SAT-237	Prognosis of alcoholic or viral B/C cirrhosis according to ABO blood group: results of abocirralvir, from CIRRAL and ANRS CO12 CirVir cohorts	Isabelle Ollivier-Hourmand	Received

FRI-238	Active role of sphingosine-1-phosphate in promoting peripheral-dominant liver fibrosis in mice model of congestive hepatopathy	Hironari Kawai	Received

THU-238	Pre-transplant sarcopenic obesity worsens the survival after liver transplantation: a meta-analysis and systematic review	Péter Hegyi	Received

FRI-239	CRV431 decreases diet- and chemical-driven fibrosis in livers of mice	Joseph Kuo	Received

SAT-239	Effect of rifaximin or norfloxacin on hepatic venous pressure gradient in patients with cirrhosis: a systematic review and meta-analysis	Yuly Paulin Mendoza	Received

SAT-240	Repeated versus single treatment of esophageal variceal ligation after esophageal variceal bleeding	Young Youn Cho	Received

FRI-240	Fibrosis progression in NASH: real- world data from the US population	LEONARDO RUIZ CASAS	Received

FRI-241	Nanoparticular bisphosphonate induces an anti-fibrotic response by modulation of fibrosis associated genes and pathways in (non-) parenchymal liver cells in CCL4 fibrotic mice	Leonard Kaps	Received

THU-241	Postreperfusion biopsy as predictor of outcomes after liver transplantation	Esteban Fuentes Valenzuela	Received

SAT-242	The predictive value of MRI-based markers of liver disease on clinical outcomes in patients with cirrhosis	Christina Levick	Received

THU-242	Sarcopenia HIBA score predicts the presence of sarcopenia and mortality in patients on the waiting list for liver transplant	Ezequiel Mauro	Received

FRI-242	Microscopy-based fibrosis phenotypic analysis of animal and human NASH cohorts reveal translational traits of fibrosis progression and severity	Li Chen	Received

FRI-243	Fibrosis phenotypic analysis of collagen stained liver histology sections discern anti-fibrotic agents in DDC- induced cholangitis mouse model	Li Chen	Received

THU-243	A novel nomogram based on liver stiffness to predict the comprehensive complication index after liver resection in patients with hepatocellular carcinoma	Federico Ravaioli	Received

SAT-243	Elast q - 2D shear wave liver elastography correlates well with vibration controlled transcient elastography in patients with different etiologies of chronic liver disease	David JM Bauer	Received

SAT-244	Liver function assessment by 13C-methacetin test before and after placement of a transjugular portosystemic shunt: a prospective pilot study	David Semela	Received

THU-244	Physical frailty predicts liver transplant waiting list mortality: United Kingdom experience	Felicity Williams	Received

FRI-245	Epigenetic mechanism and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNA methyltransferase 1 for the inhibition of liver fibrosis	Maite G Fernandez-Barrena	Received

THU-245	Early versus late hepatocellular carcinoma (HCC) recurrence after liver transplantation for HCC: patterns and long-term outcome	Faouzi Saliba	Received

THU-246	Epidemiology, features and outcome of patients transplanted for hepatocellular carcinoma in the last decade: a single-center experience	Federica Invernizzi	Received

FRI-246	FIB-4 and APRI scores re-validation; a cohort study of 69106 chronic hepatitis C patients	Hend Shousha	Received

SAT-246	Endothelin-1 level at first presentation of hematemesis as indicator of recurrent bleeding within 5 days	Ahmed Ibrahim	Received

SAT-247	Spleen acoustic radiation force impulse (ARFI) elastography predicts decompensation in patients with liver cirrhosis	Elba Llop	Received

THU-247	Early recurrence of hepatocellular carcinoma after liver transplantation can be predicted by FDG-PET and microvascular invasion at explant pathology	Federica Invernizzi	Received

SAT-248	Automatic high-risk fibrosis score prediction using computed tomography imaging	Elton Rexhepaj	Received

THU-248	Re-establishing abstinence after alcohol relapse after early transplant (LT) for alcoholic hepatitis (AH) provides survival advantage	George Therapondos	Received

SAT-249	The variscreen algorithm using successively platelets, liver stiffness and INR improves and secures the screening of esophageal varices needing treatment	Federico Ravaioli	Received

THU-249	Predictors of success in the treatment of anastomotic biliary stricture after liver transplantation	Helena Katchman	Received

FRI-250	Hepatocytic C-jun NH2 terminal kinase activity confers protection against cholestatic liver injury in mice	Mohamed Ramadan Mohamed	Received

THU-250	Survival after liver transplant in recipients of different age groups: a systematic review and meta-analysis	Ho Ming CHENG	Received

SAT-250	Breath-based monitoring of liver metabolism using exogenous volatile organic compounds - towards improved detection	Giuseppe Ferrandino	Received

SAT-251	Intelligent liver function testing in action: a one-year review	Iain Macpherson	Received

THU-251	Prophylactic rifaximin use in liver transplant candidates is associated with false positive results of the alcohol biomarker, ethyl sulphate	Ian Webzell	Received

SAT-252	ALT level in the diagnosis of chronic liver disease and advanced fibrosis	Iain Macpherson	Received

THU-252	Predictive factors of symptomatic nodular regenerative hyperplasia after liver transplantation	Ilias Kounis	Received

THU-253	Transplanting livers from hepatitis C positive donors: is it worth the risk?	Jacobus Mensink	Received

FRI-253	Non-invasive test cut-offs for the identification of advanced liver fibrosis in a diabetes cohort with non-alcoholic steatohepatitis: data from the phase 3 AURORA study	Quentin M Anstee	Received

SAT-254	Serum keratin 19 (CYFRA 21-1) links ductal reaction with portal hypertension and outcome of advanced liver disease	Karim Hamesch	Received

THU-254	Long-term outcomes of persistently positive hepatitis B surface antigen after liver transplantation for chronic hepatitis B	James Fung	Received

FRI-255	The impact of LOXL2 inhibition on fibrosis progression in-vitro and in-vivo	Sarah Townsend	Received

SAT-255	Relationship between Laennec histological subclassification of cirrhosis and clinical stage, grade of portal hypertension and liver stiffness	Lejealle Clement	Received

SAT-256	Evolving imaging in biliary disease: quantitative magnetic resonance cholangiopancreatography findings correlate with the modified Amsterdam score in patients with primary sclerosing cholangitis	Adriana Roca	Received

FRI-256	Hydrophobic bile acids promote proliferation and activation of hepatic stellate cells by PI3K-dependent mechanisms	Sebastian Zimny	Received

THU-257	Hepatitis B immunoglobulin prophylaxis for prevention of de novo Hepatitis B infection from hepatitis B core antibody-positive donors	Kyeongdeok Kim	Received

SAT-258	Systemic light chain AL with cardiac and liver involvement can be predicted by transient elastography	Speranta Iacob	Received

FRI-258	Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients	Stephen A. Harrison	Received

SAT-259	Validating the Swansea criteria in a single-centre study with cohorts of patients with acute fatty liver of pregnancy and haemolysis, elevated liver enzymes and low platelets syndrome: is it time to modify the criteria?	Mussarat Rahim	Received

FRI-260	Aspirin induces autophagy and alleviates liver fibrosis by reducing oxidative stress and inflammation in mice model of chronic liver injury	Adil Bhat	Received

THU-260	Assessment of long-term risk of cardiovascular disease after liver transplantation	Kirsty Miles	Received

SAT-261	Heat shock protein 47 is associated with fibrogenesis in alcoholic liver disease	Pernille Juhl	Received

SAT-262	Dysregulation of wound healing status and activity is associated with fibrosis and inflammation in early alcohol associated liver disease	Pernille Juhl	Received

FRI-262	(pro)renin receptor knockdown attenuates liver fibrosis through inactivation of ERK/TGF- ?1/Smad3 pathway	Yun-Cheng Hsieh	Received

THU-262	Portal venous thrombosis and liver transplant: incidence and evolution in the 1st year after transplant	MARIA ANGELES LOPEZ GARRIDO	Received

FRI-263	Diagnostic accuracy of liver stiffness measurement by fibroscan in liver transplant recipients	Zeynep Melekoglu Ellik	Received

SAT-263	Liver stiffness measurement using acoustic radiation force impulse elastography is a good predictor of hepatic decompensation in pregnant cirrhotic patients	Omar Elshaarawy	Received

THU-263	Utility of anticoagulation in portal venous thrombosis before and after liver transplant	MARIA ANGELES LOPEZ GARRIDO	Received

THU-264	Safety and efficacy of a cardiac risk stratification protocol based on traditional cardiac risk-factors in patients undergoing liver transplantation	Marcus Robertson	Received

FRI-264	Improvements in the ELF test are associated with widespread changes in the hepatic transcriptome in patients with advanced fibrosis due to non-alcoholic steatohepatitis	Marianne Camargo	Received

SAT-264	Reliablility criteria will discriminate accuracy of blood liver fibrosis tests	Paul Cales	Received

SAT-265	The usual blood liver markers provide a performant fibrosis test thanks to artificial intelligence	Paul Cales	Received

FRI-265	Contrast-enhanced ultrasound algorithms for the non-invasive diagnosis of hepatocellular carcinoma in high-risk patients - a prospective multicentre study (DEGUM-CEUS HCC trial)	Barbara Schellhaas	Received

THU-265	Projection of liver transplant activity per indication in France and United Kingdom	Mark Connolly	Received

SAT-266	A gut microbiota and liver co-metabolized biomarker to monitor liver cirrhosis progression with different etiologies in humans	Jia-bo Wang	Received

THU-266	The impact of gender and comorbidity burden on liver transplant eligibility and patient survival	Marwan Ghabril	Received

SAT-267	Serum metabolic biomarkers for the differential diagnosis of distal cholangiocarcinoma and pancreas ductal adenocarcinoma	Rocio IR Macias	Received

THU-268	Accuracy of triple echo MRI in predicting hepatic steatosis in potential liver donors	Mohammed Aljawad	Received

SAT-268	Proteomic identification of serum factors that correlate with reduction of HVPG following curative treatment for hepatitis C virus infection	shola richards	Received

FRI-269	Ph-responsive polymersomes for matrix metalloproteinase-1 delivery as a promising therapeutic strategy for the treatment of liver fibrosis	Eline Geervliet	Received

SAT-269	Genome-wide association study (GWAS) of circulating liver enzymes identifies 300 novel variants with distinct tissue expression patterns and gene set enrichment	Katarina Gluic	Received

FRI-270	Diagnostic value of magnetic resonance elastography in cirrhotic portal hypertension	Guanhua Zhang	Received

THU-270	Positive complement-dependent cytotoxicity crossmatch results do not influence long-term graft or patient survival following liver transplantation	Neil Halliday	Received

SAT-270	Virtual touch quantification using acoustic radiation force impulse technology versus transient elastography for the non-invasive assessment of liver fibrosis in patients with chronic hepatitis B or C using liver biopsy as gold standard	Baldea Victor	Received

SAT-271	Quantitative magnetic resonance cholangiopancreatography imaging in patients with primary sclerosing cholangitis - feasibility and preliminary analysis for prediction of clinical outcomes	VIjay Are	Received

THU-272	Clostridium difficile infection in liver transplant recipients is uncommon and does not impact long-term survival: a case-control study	Nicholas Kortt	Received

SAT-272	Two-dimensional real-time shear wave elastography and risk for de novo hepatocellular carcinoma in patients with advanced chronic liver disease	Wenyi Gu	Received

SAT-273	Progress in hepatitis C testing as a part of the hepatitis C elimination program in Georgia	Amiran Gamkrelidze	Received

FRI-273	Kahweol activates Nrf2/HO-1 by a pathway different from p62 and autophagy dependent degradation	Byoung Kuk Jang	Received

FRI-274	Role of Kupffer phase image using sonazoid on CEUS LI-RADS and diagnostic performance for hepatocellular carcinoma	Jeong Ah Hwang	Received

SAT-274	Evaluation of hepatitis B virus (HBV) epidemiology, vaccine impact and treatment eligibility: a census-based community serological survey in Blantyre, Malawi	Alexander Stockdale	Received

THU-274	Patient social and lifestyle factors associated with cardiovascular risk affect decisions regarding transplant candidacy more than factors associated with psychological and financial well-being	Oliver Tavabie	Received

SAT-275	HCV in addiction care: different epidemiology, excellent treatment results	Andrea Afonso Díaz	Received

THU-275	Inequality in access to liver transplant: are satellite liver transplant centres the answer?	Oliver Tavabie	Received

FRI-275	Impact of contrast-enhanced ultrasound on detection of colorectal liver metastases and therapeutic strategy in patients with newly diagnosed colorectal carcinoma after staging with computertomography. A prospective cohort study	Mikael Sawatzki	Received

SAT-276	Modelling the cost of hepatitis C virus transmission in Pakistan	Aaron G. Lim	Received

FRI-276	The phenotype of compound heterozygous BSEP deficiency patients is determined by the combined residual function of the two ABCB11 mutations: results from the NAPPED consortium	Antonia Felzen	Received

SAT-277	The best strategy for retrieval of hepatitis C patients lost to follow up: randomized clinical trial	Alberto Hernández Bustabad	Received

FRI-277	Proteostasis improvement in cystic cholangiocytes alleviates endoplasmic reticulum stress and halts polycystic liver disease	Alvaro Santos-Laso	Received

THU-277	Poor dental health is a risk factor for infections by streptococci after liver transplant	Philipp Lutz	Received

THU-278	Pre-formed donor specific antibodies and aetiology of liver disease are associated with increased incidence of acute cellular rejections after liver transplantation	Preya Patel	Received

SAT-278	Is hospital admission an ideal condition for HCV screening? A survey from the Venetian area (north-east of Italy)	Alessandro Caroli	Received

SAT-279	A novel microsimulation model of chronic hepatitis B (HBV): validation of HBV viral dynamics and cumulative incidence of hepatocellular carcinoma	Amir Mohareb	Received

SAT-280	Rapid test & treat programme successfully facilitating hepatitis C micro-elimination in a womens prison	Andrew Ustianowski	Received

FRI-280	Custom-designed next generation sequencing panel for genotype identification in cholestasis	Carola Drge	Received

FRI-281	ABCB4/MDR3 gene mutations in young patients with symptomatic cholelithiasis	Catarina Gouveia	Received

SAT-281	Role of immigration in chronic HBV and HCV infection in our environment. Origin and characteristics of the patients	Ángela Suárez-Noya	Received

THU-281	Incidence and prognostic impact of cancer after liver transplantation	Manuel Rodríguez-Perálvarez	Received

THU-282	Gender disparity in cardiovascular morbidity and mortality post liver transplantation	Samarth Patel	Received

SAT-282	From stagnation to elimination: tracking hepatitis C elimination policy implementation in Europe in partnership with patient organizations	Adam Palayew	Received

FRI-282	Efficacy of zinc on human hepatic copper uptake depending on zinc type and dose regimen quantified with 64-CuCl2 PET/CTscan	Ditte Emilie Munk	Received

THU-283	GFR reset point at 3 months after liver transplant is a superior predictor of liver and kidney disease related outcomes: analysis from a large cohort of NASH patients (nail NASH consortium)	Sanjaya Satapathy	Received

FRI-284	Impact of nitisinone treatment and discontinuation on the metabolome of wild type and hereditary tyrosinemia type 1 mice	Haaike Colemonts-Vroninks	Received

THU-284	Is hepatitis B immunoglobulin necessary for hepatitis D prophylaxis after liver transplantation? A retrospective multicenter study of a cohort of 174 patients	Sergio Rodriguez Tajes	Received

SAT-284	Treatment cascade of hepatitis C in a non-university hospital setting, that uses a hub-and-spoke model, in southern Switzerland	Adriana Baserga	Received

THU-285	Pre-transplant diabetes independently predicts atherosclerotic vascular event and death due to cardiovascular disease in liver transplant recipients: a long term multicenter observational study	Margherita Falcini	Received

FRI-285	Prognosis in persons with an HFE-mutation: population-based cohort study of 3,645 individuals	Hannes Hagstrm	Received

SAT-285	A nurse led hepatitis C model of care in primary care and community services in Melbourne, Australia	Brendan Harney	Received

FRI-286	Cracking the notch code in alagille syndrome: single-cell receptor-ligand interactions and outcomes in vivo, and an emerging role of immune cells	Jan Maek	Received

SAT-286	Barriers to hepatitis C virus elimination in Germany: why arent diagnosed patients initiating therapy?	Jeff Lehman	Received

FRI-287	Real-world disease burden, treatment patterns, and outcomes of hospitalized patients with hepatic encephalopathy	Teresa Tiencken	Received

THU-287	Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or mortality	Thomas Horvatits	Received

FRI-288	Liver ultrasonic transient elastometry (fibroscan (r)) in hepatic amyloidosis : results of a multicenter cohort of 26 cases	Jean-Franois Cadranel	Received

SAT-288	Description of HBV-infected persons presenting late to specialist care in 10 Spanish centres: A retrospective registry review	Camila A Picchio	Received

THU-288	An open-label, cohort study of grazoprevir/elbasvir combination therapy for patients with genotype 1b chronic hepatitis C after liver or kidney transplantation	Teng-Yu Lee	Received

SAT-289	The prevalence of hepatitis C amongst people who use performance and image enhancing drugs - a systematic review	Charlotte Cook	Received

FRI-289	Directed protein evolution as a tool to innovate gene therapy for hereditary tyrosinemia type 1	Jessie Neuckermans	Received

SAT-290	Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study)	Clotilde Lepers	Received

THU-290	Usefulness of the AFP model to predict recurrence tumor in patients transplanted with carcinoma hepatocellular within Milan criteria	Víctor Jiménez Beltrán	Received

SAT-291	Hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington, USA	Maria Corcorran	Received

THU-291	Therapy with DAA increases post-OLT survival but not the risk of recurrence in patients undergoing liver transplantation for HCV-related HCC	Vito Sansone	Received

FRI-292	Genome-wide protective variants in MARC1 and HSD17B13 are associated with reduced inflammation and lower fibrosis stage on biopsy in children with NAFLD	Jake Mann	Received

SAT-292	Dried blood spots are a useful tool for hepatitis A screening in the pandemic areas with medical resource-limited condition	Chikako Yamamoto	Received

THU-292	Geographic disparities and socioeconomic determinants in liver transplantation referral at the Scottish Liver Transplant Unit	Wilson Siu	Received

SAT-293	Viral hepatitis in Belgian prisons: a first-time multicenter prevalence study	Dana Busschots	Received

FRI-293	Non-invasive screening for liver fibrosis by acoustic radiation force impulse in patients with ciliopathies	Johanna Bresch	Received

THU-293	Pre-operative biliary drainage in perihilar cholangiocarcinoma: an overview of systematic reviews	Xinwei Chang	Received

SAT-294	Limburg is the first Belgian province on track for hepatitis C virus eradication in the most important group at risk: People who use drugs	Dana Busschots	Received

THU-294	Imprints of post-liver transplantation: HCV recurrence on immune cell compartment persist despite achieving therapy-induced SVR	Amare Aregay	Received

FRI-294	Cholestatic phenotype of a mouse model for organic solute transporter ? (OST?/SLC51B) deficiency suggest a role of the beta subunit beyond an OST? chaperone	Stan van de Graaf	Received

SAT-295	Early treatment of hepatitis C virus improves health outcomes and yields cost-savings: A modeling study in Argentina	Diego Kanevsky	Received

FRI-295	Comparative pharmacokinetic profile of two distinct trientine salt formulations used for treatment of Wilsons disease	Henry Abela	Received

SAT-296	Tailored message interventions promote the number of participants in viral hepatitis screening for Japanese workers - multicenter trial of 1,127,596 general checkup applicants	Masaaki Korenaga	Received

FRI-296	Differential expression of bile acid subspecies with maralixibat treatment in pruritus responders with bile salt export pump deficiency	Kenneth Setchell	Received

THU-297	Hepatic ischemia induces a time-dependent increase in SERPINB3 gene expression	CLARISSA BERARDO	Received

FRI-297	Clinical, histological, and biochemical liver phenotype of European adults with heterozygous alpha-1 antitrypsin deficiency (PiMZ genotype)	Karim Hamesch	Received

SAT-297	Data from a large, public sector hepatitis C program in Punjab, India	Sajal Marwaha	Received

SAT-298	Implementation of electronic monitoring and evaluation system for hepatitis C in Punjab, India	Sajal Marwaha	Received

FRI-298	Customized xenograft model development: liver repopulation of FRG KO mice with primary hepatocytes from donors carrying specific genetic variants	LANDER FOQUET	Received

FRI-299	Alpha-1-antitrypsin deficiency liver disease: patients lost in the system	Maria Angeles Ruiz-Ramirez	Received

FRI-300	Neurodegenerative patterns in Wilsons disease with hepatic or neurological manifestation assessed by morphometric magnetic resonance imaging	Marlene Panzer	Received

SAT-300	Unusual occurrence of hepatitis B infection in Upper Egypt	Mahmoud S. Elzalabany	Received

FRI-301	Liver transplantation for acute intermittent porphyria in Europe	Mattias Lissing	Received

SAT-302	Classifying people living with hepatitis C virus using a population-level latent class analysis to inform optimal integration of health services	Emilia Clementi	Received

FRI-302	Magnetic resonance iron quantification facilitates venesection decision making in iron overload	Meha Bhuva	Received

FRI-303	Major depressive disorder in patients with Wilsons disease: relationship with liver disease, neurological disease and quality of life	Michelle Camarata	Received

FRI-304	Mortality in patients with Wilsons disease in England: a national register-based study	Michelle Camarata	Received

SAT-304	Hepatitis C virus testing and treatment in children: results from a global paediatric policy review	Farihah Malik	Received

THU-304	Serum glycomics early after liver transplantation relate to graft loss 3 months after liver transplantation independently of early allograft dysfunction	Verhelst Xavier	Received

FRI-305	Survival in HFE hemochromatosis: influence of polymorphisms in HSD17B13, GNPAT, and PCSK7	Moritz Tobiasch	Received

FRI-306	Analysis of survival and influence of genetic modifiers in HFE- and non-HFE-associated iron overload	Moritz Tobiasch	Received

SAT-306	Relationship between metabolic syndrome and ALT level with normal range in the general population	Won Sohn	Received

FRI-307	Validation of the new proposed histological criteria for the diagnosis of porto-sinusoidal vascular disease in a single tertiary center	Oana Nicoara-Farcau	Received

SAT-307	Are UK NAFLD/NASH referral pathways ready to tackle the emerging epidemic? A rapid systematic public health evidence synthesis	Hannah Pheasant-Oldfield	Received

THU-308	Unravelling the molecular determinants of metabolic syndrome thanks to NMR-metabolomics of urine and serum samples	Chiara Bruzzone	Received

FRI-308	Non-invasive diagnostic tools in porto sinusoidal vascular liver disease. A pilot study	Oana Nicoara Farcau	Received

SAT-309	Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study	Heather Valerio	Received

THU-309	The hedgehog effect: mediating crosstalk between liver and adipose tissue	Fritzi Ott	Received

THU-310	MicroRNA-26b-5p sensitizes hepatocellular carcinoma CD133 cancer stem cells to cisplatin through downregulation of Jag1-Hes1 and increased BBC3-mediated apoptosis	Hamed Hemati	Received

FRI-310	A phase 1/2 open label extension study of givosiran, an investigational RNAi therapeutic, in patients with acute intermittent porphyria	Francesca Worthington	Received

SAT-310	Searching for patients lost in the system with chronic hepatitis C in a tertiary hospital: a problem still to be solved	Irene Andaluz	Received

SAT-311	Economic evaluation of the hepatitis C virus screening and treatment program in Georgia	Irina Tskhomelidze	Received

FRI-311	Good clinical outcomes after direct intrahepatic portocaval stent (DIPS) insertion for Budd-Chiari syndrome	Rosemary Faulkes	Received

SAT-312	Assessing the level of detection of hepatitis C virus RNA in individuals with detectable viremia following treatment with direct acting antivirals: and opportunity for new testing technologies	Jake Morgan	Received

THU-312	Decreased expressions of p70S6K in NK cells of F4-NAFLD patients inhibited F-actin and was correlated with their impaired function	Johnny Amer	Received

FRI-312	Clinical features and natural history of 1154 Alagille syndrome patients: results from the international multicenter GALA study group	Shannon M. Vandriel	Received

SAT-313	A population-based intervention to improve care cascade of patients with hepatitis C infection	John Scott	Received

THU-313	A fatty acid amide hydrolase inhibitor, URB597, inhibits MICA and MICB shedding	Kazuma Sekiba	Received

FRI-314	Wilsons disease: epidemiologic and therapeutic insights from German hospital and ambulatory invoicing data	Steffen Wahler	Received

SAT-314	Do countries have the right policies to eliminate viral hepatitis B and C: a secondary analysis of the Lancet GastroHep viral hepatitis commission	Jeffrey Lazarus	Received

SAT-315	Validation of a novel rapid point-of-care ALT test in patients with viral hepatitis	Jess Howell	Received

FRI-315	AN ULTRASONOGRAPHY-ELASTOGRAPHY SCORE TO SUSPECT PORTO-SINUSOIDAL VASCULAR DISEASE IN PATIENTS WITH PORTAL VEIN THROMBOSIS	Stefania Gioia	Received

FRI-316	Elevated serum bile acid and alanine aminotransferase concentrations in intrahepatic cholestasis of pregnancy are associated with increased fetal NT-proBNP which is ameliorated by ursodeoxycholic acid treatment	Tharni Vasavan	Received

SAT-316	Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic hepatitis C virus in low- and middle-income settings	JOSEPHINE WALKER	Received

THU-316	The FXR agonist obeticholic acid decreases matrix metalloproteinase activity via RECK and TIMP modulation in hepatic ischemia/reperfusion injury	Laura Giuseppina Di Pasqua	Received

SAT-317	Cross-sectional associations between suspected non-alcoholic fatty liver disease, diabetes, and hypertension in hispanic adults living in the San Juan metropolitan area	Josheili Llavona	Received

FRI-317	Penetrance, cancer incidence and survival of hemochromatosis in a long-term follow-up and epidemiological modelling study	Thomas Kallab	Received

THU-317	Cross-linking of liver metabolism - hedgehog as a key regulator of energy metabolism, regulating mechanistic target of rapamycin activity	Luise Spormann	Received

FRI-318	Prevalence and characteristics of cystic fibrosis associated-liver disease in a cohort of cystic fibrosis patients	Zaina Issa	Received

SAT-318	HCV care cascade of PWID enrolled in methadone substitution treatment program in Georgia - is this the first group of population in which hepatitis C will be eliminated in Georgia?	Ketevan Stvilia	Received

THU-318	Functional consequences of metabolic zonation in murine livers: new insights for an old story	Madlen Matz-Soja	Received

THU-319	PXB-cells for the study of lipid metabolism: robust and human-specific lipid profile in human hepatocytes freshly isolated from chimeric mice with humanized liver	Masaki Takahashi	Received

FRI-319	Liver cirrhosis development and value of transient elastography among a large cohort of Wilsons disease patients with a long-term follow-up in Spain	Zoe Mariño	Received

SAT-319	Screening and linkage to care of prisoners with HCV infection: the resist-HCV project	Lorenza Di Marco	Received

THU-320	Ductular reaction and its microenvironment is aetiology driven	Matthias Van Haele	Received

FRI-320	Employment after liver transplantation and contributing factors	Anna van den Burg	Received

SAT-320	Frequency of prenatal hepatitis C screening and diagnosis in British Columbia, 2008-2018	Margo Pearce	Received

FRI-321	Development of a district general hospital liver nurse service for patients with acute and chronic liver conditions	Amy Thatcher	Received

SAT-321	Re-capturing a lost population - the benefits of a nurse-delivered HCV community cirrhosis clinic	Maryam Noeman	Received

THU-322	Screening of components involved in activation of innate immune responses and inflammation in NEMO KO mice	Mick Frissen	Received

FRI-322	Managing decompensated cirrhosis - the importance of multidisciplinary engagement	Dev Katarey	Received

SAT-323	Preliminary results of the prevalence of non-alcoholic fatty liver disease among the greater Toronto area population	Magdy Elkhashab	Received

THU-323	Establishment of murine model of acute-on-chronic liver failure	Nidhi Nautiyal	Received

FRI-323	The first step towards comprehensive nurse-led hepatology care: evolution of the Hull specialist liver nurse service (SLNS)	Dianne Backhouse	Received

SAT-324	Suboptimal linkage to care after identification of serum hepatitis B surface antigen-positive individuals in territory-wide screening: a need for educational and public health policies	Kwan Lung Ko	Received

FRI-324	Prospective study of therapeutic education (TE) designed with a multidisciplinary team and participation of patients to improve the adherence to treatment of the patients and their quality of life (QOL)	Dominique Larrey	Received

FRI-325	Hepatitis B testing in Bcr-Abl tyrosine kinase inhibitor therapy	Fatema Jessa	Received

THU-325	Bioengineering of 3D bile ducts from 2D micropatterns by self-organogenesis	Pascale Dupuis-Williams	Received

SAT-326	Microelimination of chronic hepatitis C in Romania - another pathway to achieve national elimination goals by HepC ALERT project	Speranta Iacob	Received

FRI-326	Impact of a nurse educational program for patient empowerment during sequential systemic therapy for hepatocellular carcinoma	Gemma Iserte	Received

THU-326	Histidine triad nucleotide-binding protein-2 is present at the cross-road of ER-mitochondria interactions and modulates adaptive stress response in hepatocytes	Pavitra Kumar	Received

THU-327	Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease	Josef Wagner	Received

FRI-328	Pilot of an advanced liver disease nurse education program and its intersection with emerging models of advanced hepatology nursing practice	Janice Prtichard-Jones	Received

THU-328	Tolerogenic dendritic cells modulate pathogenic CD4 T cells in an ex vivo co-culture system in a concanavalin A -mice model of type-I autoimmune hepatitis	Prabhsimran Singh	Received

FRI-329	Diet lifestyle management of non-alcoholic fatty liver disease (NAFLD): a cross-sectional survey of clinicians	Laura Haigh	Received

SAT-329	Incidence of HCV infection among gbMSM in British Columbia, Canada: a population-based cohort study	James Wilton	Received

FRI-330	Development of clinical professional standards for liver transplant nursing	Michelle Clayton	Received

THU-330	Cirrhotic extracellular matrix affects Hic-5 expression in primary human hepatic stellate cells	Simona Onali	Received

SAT-330	An OST (opiate substitution therapy)-based hepatology service facility (OHSF) with access to chronic hepatitis C treatment: the example of an one stop shop as a practical step towards HCV elimination in patients who use drugs (PWUD)	Nikolaos Papadopoulos	Received

SAT-331	Recent decline in hepatocellular carcinoma rates in the United States	THOMAS OBRIEN	Received

FRI-331	Nurse assisted follow-up after admission with decompensation in cirrhosis: a systematic review and meta-analysis	Malene Barfod OConnell	Received

THU-331	Phenotypic characterization of ABCG5/G8 deficiency: ive knockout in liver or intestine leads to genocopies	Susanne N Weber	Received

FRI-332	Prospective evaluation of a non-alcoholic fatty liver disease assessment pathway; impact of clinical nurse specialist role	Marie McGrath	Received

SAT-333	Development of a supportive needs assessment tool for cirrhosis (SNAC)	Patricia Valery	Received

FRI-333	Illustrations supporting patient counseling before and after liver transplantation	Patrizia Kuenzler-Heule	Received

THU-333	Upregulation of CCNB1, CDC20 and CENPF genes is associated with poor prognosis in hepatocellular carcinoma (HCC)	Tengfei Si	Received

FRI-334	Soluble CEACAM1 induces regulatory T cells in vitro	Andrea Kristina Horst	Received

SAT-334	Inequities in presentation and outcomes for indigenous Australians hospitalised for cirrhosis	Patricia Valery	Received

THU-334	Bax inhibitor-1 inhibits acetaminophen induced hepatotoxicity by reducing the drug induced ER stress through regulating the RIDD activity of IRE1 alpha	Thoufiqul Alam Riaz	Received

THU-336	CircRNA_104797 mediates acquired sorafenib resistance in hepatocellular carcinoma through regulating ROS	Junjie Xu	Received

SAT-336	Catalytic funding of viral hepatitis elimination program in Uzbekistan	Rick Dunn	Received

SAT-337	Meta-analysis: accuracy of the enhanced liver fibrosis (ELF) test in detection of advanced fibrosis or cirrhosis	Richard Parker	Received

THU-337	Ubiquilin 1 mediates sorafenib resistance in hepatocellular carcinoma through targeting mitochondrial biogenesis via regulating PGC1?	Junjie Xu	Received

SAT-338	Risk factors for liver disease cluster geographically: precision public health analysis of a UK city	Richard Parker	Received

THU-338	Investigating the mechanism of treating acute-on-chronic liver failure with human bone marrow-derived mesenchymal stem cells via hepatocytes exosomal miRNAs	ZHANG JING	Received

FRI-338	Plasmacytoid dendrtic cells protect against acute liver injury via IL-35	Yuzo Koda	Received

THU-339	A novel hepatitis C intervention in Denmark to test and treat people who inject drugs	Anne vrehus	Received

SAT-339	Updated estimate for prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin	Robert Wong	Received

THU-341	Kidney transplant from hepatitis C positive donors to hepatitis C negative recipients: report on the first experience in the UK	Brendan Healy	Received

FRI-341	Myeloid derived suppressor cells enhance regulatory T cell suppressive activity via IL-10, iNOS and PDL-2 in cirrhotic patients with sepsis	Rashi Sehgal	Received

SAT-341	Comparison of costs of different HCV screening and linkage to care interventions across Europe	Zoe Ward	Received

FRI-342	Neutrophils are recruited at the periportal area in alcoholic liver disease and promote ductular reaction expansion	Silvia Ariño Mons	Received

THU-342	Pharmacy-based molecular point-of-care testing for hepatitis C (HCV) in high-risk patients: feasibility and linkage to care	Benedict Rogers	Received

SAT-342	High patient acceptability for a hepatitis C mobile outreach service targeting vulnerable homeless communities - an important component for elimination?	Sarah Montague	Received

SAT-343	Health and economic burden due to alcohol related liver diseases in New Delhi, India: a Markov probabilistic modelling approach	Shiv Kumar Sarin	Received

THU-344	Screening and treatment difficulties of hepatitis C virus infected patients with substance use disorders or dual pathology, despite centralized management in an addiction and dual diagnosis center	Cristina Marcos Fosch	Received

FRI-344	Drug screening against complement disorders using human stem cell-derived endothelium and liver organoids	Yasunori Nio	Received

THU-345	Integrating hepatitis C virus screening by dry blood spot test into colorectal cancer screening: a randomized controlled trial	María Cristina Reygosa Castro	Received

SAT-345	National survey among people who use drugs (PWUD) on opioid substitution treatment (OST) on their knowledge of hepatitis C virus (HCV) infection and barriers for treatment in Bulgaria	Marieta Simonova	Received

THU-346	Ethnic disparities in the risk of hepatitis C virus-related diabetes in a large population-based cohort in Canada	Dahn Jeong	Received

SAT-346	Demonstration of the feasibility of two innovative models of HCV testing and treatment in two unique populations in Punjab and Delhi, India-head- start project, India	Preetishirin Katapur	Received

SAT-347	Barking up the wrong tree: why universal hepatitis C virus screening is not enough for its elimination in the US	Pimsiri Sripongpun	Received

FRI-347	Platelet activation during chronic hepatitis B infection exacerbates liver inflammation and promotes fibrosis	Qirong Jiang	Received

THU-347	The electronegative low-density lipoprotein in patients with chronic hepatitis C infection	Chia-Yen Dai	Received

FRI-348	Entecavir-induced interferon-lambda 1 suppresses innate lymphoid cells 2 in patients with hepatitis B virus-related liver cirrhosis	Siqi Wang	Received

SAT-348	From emergency department automated hepatitis B & C screening to care and cure in a primary care practice	Su Wang	Received

THU-348	Telemedicine and decentralized treatment dispensation to rescue patients in a hepatitis C micro-elimination program based on on-site dried blood spot testing in drug addiction centers	Dalia Morales Arraez	Received

FRI-349	A new therapeutic candidate vaccine can overcome hepatitis B virus-induced immune tolerance in a mouse model of chronic infection	Babak BAYAT	Received

THU-349	The success of outreach hepatitis C screening among a Belgian population of drug users in a rural and urban setting	Dana Busschots	Received

FRI-350	Potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with toll-like receptor 8 (TLR8) agonist selgantolimod	Diana Chen	Received

THU-350	Angiopoietin 2 levels decrease with SVR and correlate with dynamics of portal hypertension in patients with HCV-induced advanced chronic liver disease	David JM Bauer	Received

SAT-350	Deleterious impact of advanced non-alcoholic steatohepatitis on multiple patient-relevant outcomes: an international, cross-sectional, real-world study	Victoria Higgins	Received

FRI-351	Immunogenicity and efficacy of an HBV vaccine with an intrinsic checkpoint inhibitor	Andrew Luber	Received

SAT-351	Factors associated with failure to link people who inject drugs to HCV care and treatment: results from a community-based seek-test-treat program in Athens, Greece (ARISTOTLE HCV-HIV)	Vana Sypsa	Received

SAT-352	Clinical and economic consequences of antiviral treatment for hepatitis C chronic infection in Europe: analysis of England, Italy, Romania and Spain data	Loreta A. Kondili	Received

FRI-352	Extracellular HBsAg clearance has minimal impact on CD8 T cell responses in mouse models of HBV pathogenesis	Valeria Fumagalli	Received

THU-353	The HSD17B13 rs6834314 variant is associated with liver stiffness measurement in untreated HCV-3 patients with cirrhosis	Enrico Galmozzi	Received

FRI-353	Analysis of regulatory T cells frequency and phenotype in chronic hepatitis C patients undergoing interferon-free therapies	Georgios Koutsoudakis	Received

SAT-353	The head-start project: introduction of rapid diagnostic tests for hepatitis C screening in primary healthcare sites as a first step towards decentralizing hepatitis C care in Malaysia	Xiaohui Sem	Received

FRI-354	Characterization of the HBV-specific T cell pool reveals shared epitope usage but different phenotypes of HBV-reactive T cells across patients	Jeffrey Wallin	Received

SAT-354	Enhancing the hepatitis B care cascade in Australia using a country-based testing program targeting new migrants: a cost-effectiveness model	Katarina Gluic	Received

SAT-355	Cost-effectiveness of mass screening for HCV in an Irish prison	Zoe Ward	Received

FRI-355	Hepatitis B virus kinetics after nucleos(t)ide-analogue withdrawal in chronic HBeAg(-) hepatitis correlates with HBV-specific CD8 response and HBsAg level	Julia Peña Asensio	Received

THU-355	Hepatitis C reflex testing in Spain in 2019: a story of success	Federico Garcia	Received

THU-356	Cracks in the hepatitis C cascade of care: real-life outreach data from four Central London services	Hui Mei Wong	Received

SAT-356	Hormone replacement therapy is associated with reduced liver cirrhosis risk and improved survival in treatment-naive hepatitis B- and/or C- infected postmenopausal women: a nationwide long-term population-based cohort study	Yuan-Tsung Tseng	Received

SAT-357	Hepatitis B virus core protein variants observed in a first-in-human placebo-controlled study of a core protein inhibitor	Emily P. Thi	Received

THU-357	Seroprevalence of hepatitis B virus co-infection among HCV infected patients screened during the national campaign for HCV eradication in Egypt	Hadeel Gamal Eldeen	Received

FRI-357	Hepatitis B virus-specific CXCR5 CD8 T cells may be related to hepatitis B virus clearance in chronic hepatitis B patients treated with pegylated interferon alpha	Li Zhang	Received

SAT-358	Clinical and molecular characterization of the human kidney as extrahepatic site of hepatitis E virus infection	Avista Wahid	Received

FRI-358	Hepatitis B virus-specific CXCR5 CD8 T cells shows stronger functional activity in a mouse model of acute hepatitis B virus infection	Li Zhang	Received

THU-358	Risk of liver and non-liver-related mortality among hepatitis C virus and human immunodeficiency virus co-infected persons in a cohort of Brazilian blood donors: a twenty-year study	Helio Ranes Filho	Received

FRI-359	Hepatitis D coinfection is associated with enhanced CXCR3 receptor expression of CD4 memory T cells and intrahepatic CXCR3 ligand expression compared to chronic hepatitis B patients.	Jan-Hendrik Bockmann	Received

THU-359	Emergency department screening for hepatitis C carriers does not improve linkage to care - a single-center prospective study	Inbal Houri	Received

SAT-359	Establishment of human induced pluripotent stem cell-derived hepatocyte-like cells permissive for serum-originated hepatitis B virus infection and allowing for covalently closed circular DNA inhibitor drug screening	Chau-Ting Yeh	Received

FRI-360	Magnitude and functionality of HEV-specific CD8 and CD4 T cell responses in asymptomatic blood donors resemble those in acute and symptomatic patients	Janine Kemming	Received

FRI-361	Peripheral soluble protein, transcriptomic, and methylation biomarkers associated with HBsAg loss in patients with chronic hepatitis B	Diana Chen	Received

SAT-361	Analysis of hepatitis B virus quasispecies in circulating viral DNA and RNA: are genotype and complexity different?	David Tabernero	Received

SAT-362	Mitochondrial DNA damage and mitochondrial dysfunction in patients with chronic hepatitis B	Dimitri Loureiro	Received

FRI-362	Tox expression on HBV-specific CD8 T cells is linked to clinical stage of chronic HBV infection	Kathrin Heim	Received

SAT-363	Differential HBV RNA and quantitative HBsAg kinetics between HBeAg() and HBeAg(-) patients with chronic hepatitis B on nucleos(t)ide analogues (NA)	Daryl LAU	Received

FRI-364	Distinct serum HBsAg levels show minimal effect on gene expression profiles of blood leukocyte subpopulations in non-viremic chronic HBV patients.	Noe Axel Rico Montanari	Received

FRI-365	Hepatitis C virus chronicity is associated with a tox-1(high), Eomes(high), T-bet(dim) and PD1(high) phenotype of HCV-specific CD8 T cells	Nils Wildner	Received

SAT-365	Characterization of acute hepatitis C virus infection and transmission clusters by next-generation sequencing among people who inject drugs in Catalonia	Elisa Martró	Received

THU-365	Global timing of hepatitis C virus elimination in high-income countries: an updated analysis	Yuri Sanchez Gonzalez	Received

SAT-366	Mathematical modeling of early hepatitis D virus kinetics in transgenic-hNTCP mice	Harel Dahari	Received

THU-366	Anticipated timing of elimination of hepatitis C virus in Canadas four most populous provinces	Yuri Sanchez Gonzalez	Received

THU-367	Acute hepatitis C virus infection: a prospective ten-year observational study of HCV-mono and HCV/HIV-coinfected patients	Julia Dietz	Received

FRI-367	Profiles of expression of costimulatory molecules OX40 and OX40l in PBMCs and levels of soluble OX40/OX40l in plasma in chronic hepatitis B patients and health subjects	Mengru Zhan	Received

THU-368	Improving the referral of hepatitis C virus positive patients to specialists through an electronic pop-up alert system	Kamil Ozdil	Received

FRI-368	Phenotypic variation among myeloid-derived suppressor cells (MDSC) in natural history phases of chronic HBV infection differentially impacts HBV-specific T cell response and homing: lack of functional normalization after anti-viral therapy	Sourina Pal	Received

SAT-368	Usefulness of dried plasma spots using a plasma separation card for serological diagnosis of chronic hepatitis B and C and reflex viral load testing	Joan Martinez	Received

FRI-369	Integrated analysis of serum immunological biomarkers in patients with chronic hepatitis C upon direct-acting antiviral treatment	Rosangela Teixeira	Received

THU-369	Predictors of disengagement or delay after hepatitis C assessment	Kathleen Bryce	Received

SAT-369	Validity of a point-of-care viral load kit for hepatitis B in a low-income setting	Corina Rueegg	Received

THU-370	Predictors of workload in a hepatitis C treatment pathway	Kathleen Bryce	Received

FRI-370	Higher proportion of responders with hepatitis B antibody levels =100 miu/ml with the trivalent HepB vaccine, Sci-B-Vac, compared to Engerix-B: results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT)	Timo Vesikari	Received

THU-371	Micro-elimination of hepatitis C in mental health care settings	Kristen McKee	Received

THU-372	Triple E (engagement, education and eradication) for patients with chronic hepatitis C infection: 2 years of results of a successful, collaborative US model for improving education, screening and linkage to care in an underserved population	Jane Ranagan	Received

FRI-373	Serum levels of circulating DNA species can predict the development of hepatocellular carcinoma in chronic hepatitis B patients under long-term oral antiviral therapy	George Papatheodoridis	Received

SAT-373	From in vivo to in vitro: ex vivo studies using primary human hepatocytes from chronically diseased liver-humanized FRG KO mice	LANDER FOQUET	Received

THU-373	Prevalence of hepatitis C in a gastrointestinal endoscopy unit. An active search for asymptomatic subjects	Laura Gomez-Escolar Viejo	Received

SAT-374	The head-start project Georgia: a three-armed, cluster, non-randomised trial of the effectiveness of two novel models of HCV confirmatory testing in harm reduction sites (HRS) in Georgia	Maia Japaridze	Received

THU-374	Why didnt I see you in my clinic? Patients with HCV positive serology but never a confirmed infection. A retrospective analysis at 10 years	Matias Estevez	Received

FRI-374	Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response?	Antonella Olivero	Received

FRI-375	Comparison of the risk of hepatocellular carcinoma in nucleos(t)ide analogue-naive chronic hepatitis B patients treated with entecavir versus tenofovir : a systematic review and meta-analysis	Hyunwoo Oh	Received

SAT-375	HBeAg seroconversion during treatment with peginterferon-alfa2a (PEG-IFN) is preceded by ion of hepatitis B virus basal core promoter and pre-core variants which are associated with decreased HBV replication	Maria Pfefferkorn	Received

THU-375	Timing of hepatitis C elimination in the United States: estimating the year each state will meet the World Health Organizations elimination targets	Carrie Bray	Received

THU-376	Managing hepatitis C in people who inject drugs (PWID) using the internist-addiction medicine-hepatology (IAHC) model to achieve Hep C micro-elimination	Naren Srinath Nallapeta	Received

FRI-376	Is it possible to stop nucleus(t)die analogue safely in patients with preemptive or preventive therapy for HBV reactivation?	Akihiro Tamori	Received

SAT-376	Targeting hepatitis B virus with CRISPR/Cas9 approach	Barbara Testoni	Received

THU-377	Testing and treatment for hepatitis C in the community pharmacy setting: an opportunity not to be missed?	Nicki Palmer	Received

SAT-378	The correlations between HBV markers and HBV cccDNA in the patients during Na treatment	Takeshi Matsui	Received

THU-378	Hepatitis C virus antigen detection as a tool for diagnosis of acute hepatitis C in patients with negative hepatitis C virus antibody	Rajneesh Kumar	Received

FRI-378	Evolution of care quality metrics for chronic hepatitis B in the hepatitis C direct-acting antiviral era	David Kaplan	Received

THU-379	Screening for chronic liver diseases in the general population reveals an unexpectedly high prevalence of hepatitis C and advanced NAFLD	Sebastian Bachmayer	Received

SAT-379	Delineating HBV transcripts from integrated viral DNA using target enrichment and long read sequencing	Nick van Buuren	Received

FRI-379	Excess body weight is associated with HBV-related HCC despite antiviral treatment	Jian Sun	Received

THU-380	Does additional information obtained from multiple visits change the timing of HCV treatment decisions	Shawn Greenan	Received

SAT-380	Prospective study of hepatitis B virus infection and its genotypes in the north-eastern India region	Premashis Kar	Received

SAT-381	Hepatitis D virus entry, replication and assembly in stem cell-derived hepatocytes	Bingqian Qu	Received

THU-381	Missed linkage to care for patients with chronic hepatitis C virus infection in a tertiary care center: results of the telepass project	Francesco Santopaolo	Received

FRI-381	Evaluation of dried plasma spot on the cobas(r) plasma separation card as a sample type for hepatitis B virus load quantification on the cobas(r) 6800 system	Ariadna Rando Segura	Received

FRI-382	Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years	Enrico Galmozzi	Received

SAT-382	Crispr/cas9-tailored hepatitis B-x protein knockdown inhibits cellular hyperplasia, invasion and tumorigenicity of HBV-infected hepatoma cells.	Preety Rawal	Received

THU-383	Impact of dysmetabolism on liver damage severity and evolution in a real-life cohort of patients treated for chronic hepatitis C	Serena Pelusi	Received

SAT-383	Cryptic HBV viremia in anti-HBC positive/HBsAg negative patients with HIV infection is frequently revealed by applying an ultrasensitive droplet digital PCR assay	Romina Salpini	Received

FRI-383	PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy	George Papatheodoridis	Received

THU-384	Direct-acting antivirals have substantially modified the profile of patients with cirrhosis who require hospitalization in Spain	Sergio Rodriguez Tajes	Received

FRI-384	Hepatitis B core-related antigen and viral loads status impacts on the risk of hepatocellular carcinoma in patients with HBeAg-negative chronic hepatitis B virus infection	Tetsuya Hosaka	Received

SAT-384	Osteopontin drives HBV replication and HBV-driven fibrogenesis and represents a novel therapeutic target to achieve functional cure in chronic hepatitis B	Sandra Phillips	Received

FRI-385	Plasma adipocyte fatty acid-binding protein and adiponectin levels are associated with fibrosis regression in nucleoside analogue-treated chronic hepatitis B: a prospective study with paired transient elastography	Rex Wan-Hin Hui	Received

SAT-386	Viral compartmentalization and carcinogenesis at single-cell level in HBV-induced hepatocellular carcinoma	Antonio Saviano	Received

FRI-386	Higher pregnancy hbcrag and pg HBV RNA concentrations are observed in treated and untreated chronic hepatitis B mothers with post-partum alt flares	Ivana Carey	Received

THU-386	Patients with hepatitis C (Redpath): a randomised controlled trial of telephone contact or offer of an incentive, in addition to a standard letter	stephen barclay	Received

FRI-387	Gender disparity in the association of interleukin-10 and interleukin-12 polymorphisms with the progression of hepatitis B virus infection in Caucasians	Janett Fischer	Received

THU-387	Overdose events among active drug users successfully treated for HCV: the impact of homelessness	Tianna Magel	Received

SAT-387	Pangenotypic therapies glecaprevir-pibrentasvir (G-P) and sofosbuvir-velpatasvir-voxilaprevir (S-V-V) after failure with interferon (IFN)-free direct-acting antiviral (DAA) treatment for hepatitis C	Steven Flamm	Received

SAT-388	A novel intrahepatic restriction factor, HMGA1, contributes to hepatitis B virus (HBV) replication in immune tolerant phase, serving as an anti-HBV target	Jingwen Wu	Received

FRI-389	Risk of hepatitis flare in inflammatory bowel disease patients with previous hepatitis B virus exposure - results from a territory-wide Hong Kong ibd registry study	Joyce Wing Yan Mak	Received

THU-390	Epidemiological evolution of viral hepatitis in uremic patients in Taiwan - the Formosa like group	Yu-Ju Wei	Received

FRI-390	Sarcopenia is associated with type 2 diabetes and sedentary lifestyle in patients with chronic hepatitis B	Luciana Diniz Silva	Received

SAT-390	Evaluation of the introduction of hepatitis C core antigen as a routine test to detect viraemia among patients with anti-HCV antibodies	stephen barclay	Received

SAT-391	Virologic causes for DAA treatment failure of chronic hepatitis C	Chun-Jen Liu	Received

THU-391	Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label,multicentre, phase 3 trial	Xiaoyu Wen	Received

THU-392	Expansion of a multidisciplinary support program for patients with addictions and hepatitis C: strategies for an effective approach	Montserrat Garcia-Retortillo	Received

FRI-392	Incidence and predictors of hepatitis B surface antigen clearance among people living with HIV and hepatitis B	Mamta Jain	Received

FRI-393	Rituximab monotherapy in anti-HBC positive patients with multiple sclerosis or neuromyelitis optica spectrum disorders is not associated with HBV reactivation	Mar Riveiro Barciela	Received

THU-393	Improvement of all HCV care cascade steps in IVDU treated with DAAs within a dedicated program	Alessandra Mangia	Received

SAT-393	Usefulness of HEV antigen determination in the diagnosis of acute hepatitis E	Víctor Jiménez Beltrán	Received

THU-394	Real-life efficacy and safety of direct-acting antivirals in patients with liver cirrhosis and history of hepatic decompensation: EpiTer-2 study	Aleksandra Berkan Kawi&324;ska	Received

FRI-395	Poor improvement of on-treatment FIB-4 index after initiation of nucleos(t)ide analogs is associated with development of hepatocellular carcinoma in both cirrhotic and non-cirrhotic chronic hepatitis B patients	Miyako Murakawa	Received

SAT-395	Resistance monitoring data from treatment-naive chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy	Xue Zhou	Received

THU-395	Concomitant use of direct-acting antivirals (DDAs) and central nervous system drugs in current chronic hepatitis C patient profile	Maria Sainz	Received

THU-396	Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users: the grand plan study	Brian Conway	Received

SAT-396	Developing a sensitive HBV genotyping assay for HBV DNA suppressed patients using both DNA and RNA sequencing	yang liu	Received

FRI-396	The integrated use of accurate virological and serological HBV markers can help identifying HBsAg-negative/anti-HBC -positive patients at higher risk of HBV-reactivation and optimizing the duration of prophylaxis in oncohematological setting	Mohammad Alkhatib	Received

THU-397	Direct-acting antiviral treatment in patients infected with a non-epidemic hepatitis C genotype in the Netherlands: results from a nationwide cohort study	Cas Isfordink	Received

THU-398	A real-world study of treating advanced liver cirrhosis due to chronic HCV infection genotype 1b with sofosbuvir ledipasvir with or without ribavirin: results from a cohort of 349 patients	CARMEN PREDA	Received

SAT-399	Significant compartment-specific impact of the RNA extraction and quantification method on the sensitivity of hepatitis E virus detection: implications for clinical care?	Patrick Behrendt	Received

FRI-399	Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium	zgr Koc	Received

THU-399	Alcohol use does not influence treatment uptake or outcomes in the DAA era	David Mackie	Received

THU-400	Influence of baseline resistance on treatment outcome in patients treated for chronic hepatitis C in Denmark: a nationwide study	christina slund	Received

SAT-400	Effectiveness of hepatitis A vaccination in human immunodeficiency virus-infected men who have sex with men during an outbreak of hepatitis A in Osaka, Japan	Hiroki Bessho	Received

FRI-400	Three HBsAg kinetic profiles in HBeAg negative infection and chronic hepatitis are associated with different chances of HBsAg clearance	Piero Colombatto	Received

SAT-401	Histopathology of hepatitis E is associated with patients immune status and preexisting liver condition	Daniela Lenggenhager	Received

THU-401	Inadvertent off label DAA treatment in the real-world and importance for virologic outcome - data from the German hepatitis C-Registry (DHC-R)	Yvonne Serfert	Received

FRI-401	Impact if HBV infection in HCV/HBV coinfected patients treated with DAAs in north Italy	Paolo Fabris	Received

THU-402	Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir	David A Smith	Received

SAT-402	Epidemiology of fulminant hepatitis A cases in Vienna - an informative case series	David JM Bauer	Received

FRI-402	Quantitative HBeAg varies in the different phases of HBV infection, and can predict therapeutic outcome in the setting of immunosuppression driven HBV reactivation	Lorenzo Piermatteo	Received

FRI-403	Development of a highly sensitive multiplex platform assay to monitor low levels of HBV DNA and pgRNA in samples from patients with chronic hepatitis B	Lisa Danzig	Received

THU-403	Resistance and phylogenetic analysis in HCV-2c infected patients within the Italian network VIRONET-C	Velia Chiara Di Maio	Received

SAT-403	Epidemiology of fulminant hepatitis E cases in Vienna - an informative case series	David JM Bauer	Received

THU-404	Grazoprevir/elbasvir for treatment of hepatitis C virus genotype 4 post kidney transplant	Faisal Abaalkhail	Received

FRI-404	Very low rates of receiving antiviral therapy among treatment eligible chronic hepatitis B virus infected patients	Robert Wong	Received

FRI-405	Impact of hepatitis B virus-related immune reconstitution inflammatory syndrome on HBsAg loss in patients co-infected with human immunodeficiency virus	Sachiyo Yoshio	Received

THU-405	Drug - drug and drug - disease interactions in the treatment of hepatitis C in patients with liver cirrhosis: a single-center experience	Ekaterina Nabatchikova	Received

SAT-405	Are we aligned with WHO international strategy to eliminate hepatitis C by 2030: real-world data from Khyber Pakhtunkhwa, Pakistan	Bakht Biland	Received

FRI-406	Response to a double dose (40 mcg) and an accelerated schedule (0-1-2 months) of hepatitis B vaccine in patients with advance cirrhosis. A prospective study	Sergio Rodriguez Tajes	Received

SAT-406	Hepatitis E seroprevalence and rate of viremia in immunocompromised patients - a systematic review and meta-analysis	Gustav Buescher	Received

THU-406	Integrated efficacy and safety analysis of GT1-6 treatment-naive, non-cirrhotic and compensated cirrhotic patients who received 8 weeks of glecaprevir/pibrentasvir	Jeff Lehman	Received

FRI-407	Presence of significant histopathology in HBeAg-positive chronic infection patients identified by four international guidelines: a Chinese multi-center study	Yidi Jia	Received

THU-407	Hepatitis C micro-elimination pilot strategy in Pakistani migrants in Catalonia through the implementation of a community intervention: interim results of the HepC-link study	Elisa Martró	Received

SAT-407	Therapeutic window for ribavirin therapy in transplant recipients with chronic hepatitis E virus infection	Midas Mulder	Received

SAT-409	Hepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010-2018	Michael Peeters	Received

THU-410	The outcome of re-treatment of relapsed hepatitis C virus infection after direct acting antiviral treatment failure in resource-limited settings	Gina Naguib	Received

SAT-410	Hepatitis E virus infection in liver transplant recipients in Sweden	Miriam Karlsson	Received

FRI-410	Evaluation of page-b and modified page-b scores to guide hepatocellular carcinoma surveillance in chronic hepatitis B patients on antiviral therapy - a territory-wide study of 32,150 subjects	Terry Cheuk-Fung Yip	Received

FRI-411	Clinical effectiveness of a newly developed and fully automated high-sensitive hepatitis B core-related antigen assay for monitoring nucleos(t)ide analogues therapy in hepatitis B envelope antigen-negative patients	Takako Inoue	Received

SAT-411	Hepatitis E virus shedding in semen of chronically, but not acute HEV infected individuals	Thomas Horvatits	Received

FRI-412	Clinical efficacy of a newly developed high-sensitive hepatitis B core-related antigen assay for monitoring hepatitis B virus reactivation	Takako Inoue	Received

THU-412	A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection	Xian Zhang	Received

THU-413	Health-related quality of life (HRQOL) before and after treatment of genotype 1 (GT1) infection with elbasvir/grazoprevir (EBR/GZR): results from the German hepatitis C registry (DHC-R)	Markus Becker-Camps	Received

SAT-414	Efficacy and safety of treatment interruption in patients with HBeAg negative chronic hepatitis B	Teresa Broquetas	Received

FRI-414	Clonal expansion of hepatocytes and state of hepatitis B virus DNA integration in patients with nucleos(t)ide analogue therapy	Ning CHOW	Received

FRI-415	Machine learning identifies immune profile to predict virological relapse after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B	Maximilian Wbbolding	Received

THU-415	Use of sofosbuvir based direct acting antiviral regimens is associated with reduced mortality in liver transplant candidates with hepatitis C	Ajay Israni	Received

SAT-415	Pegylated interferon beta strongly reduces all serological and intrahepatic hepatitis B virus parameters in immunodeficient humanized mice	Andrea Pirosu	Received

FRI-416	Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis	Yandi Xie	Received

THU-416	Factors associated with efficacy of retreatment with grecaprevir/pibrentasvir therapy in prior DAA failed patients - nationwide multicenter study in Japan	Jun Itakura	Received

SAT-416	hzVSF, a novel HBV therapeutic candidate, shows WHsAg loss in woodchuck hepatitis model and safety in phase I clinical study	Byoung Ahn	Received

SAT-417	Safety and efficacy of up to 76 weeks 10mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis	Alessandro Loglio	Received

THU-417	Impact of the universal access to direct-acting antivirals in the profile of hepatitis C treated patients	Jordi Llaneras	Received

SAT-418	Correlation between HBV core-related antigen and the new quantitative IGG anti-core in treated caucasian HBeAg-negative patients and inactive carriers with and without a functional cure	Alessandro Loglio	Received

FRI-418	Estimating the clinical and economic burden of chronic hepatitis B (CHB) in the United States	Carey Escheik	Received

THU-418	Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - data from the German hepatitis C-registry (DHC-R)	Yvonne Serfert	Received

FRI-419	Exaggerated risk of vitamin B12 deficiency after HCV eradication with direct-acting antivirals	Diego Casas Deza	Received

SAT-419	The establishment of hepatitis B care and treatment clinics with viral load testing capacity in the United Republic of Tanzania: a demonstration project following WHO guidelines, Zanzibar, 2017-2019	Ali Salum	Received

THU-419	HCV in the Australian primary care setting: real-world effectiveness of 12 weeks of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C	Joss OLoan	Received

SAT-420	Nucleos(t)ide analogue therapy decreases the HBeAg loss rate in HBeAg positive chronic hepatitis B patients with hepatitis flare: a propensity score matching study	Chien-Wei Peng	Received

FRI-420	Risk of hepatocellular carcinoma recurrence in patients treated with direct acting antiviral therapy	Asmaa Gomaa	Received

THU-420	Effectiveness of 8 weeks of glecaprevir/pibrentasvir in treatment-naive hepatitis C patients with liver cirrhosis: results from the real-world Spanish Hepa-C registry	Juan Turnes	Received

THU-421	Baseline features of hepatitis C patients associated to prescription of pangenotypic antiviral treatments: results from the real-world Spanish Hepa-C registry	Juan Turnes	Received

SAT-421	Long-term risk of primary liver cancers in tenofovir versus entecavir treatment for chronic hepatitis B	Chao-Hung Hung	Received

FRI-421	Evidence of declining HCV transmission in Australia following scale-up of direct acting antiviral therapy	Gregory Dore	Received

FRI-422	HIV co-infection is associated with lower risk of liver cancer after HCV-cure	ANAIS CORMA-GOMEZ	Received

THU-422	The English hepatitis C registry shows only a modest effect from non-completion of directly-acting antivirals for hepatitis C: SVR rates over 80 in genotype 1, 2 or 3 HCV if more than one third of planned treatment is completed	Kate Drysdale	Received

SAT-422	ATI-2173, a novel phosphoramidate nucleoside prodrug for HBV cure regimens	Douglas Mayers	Received

FRI-423	Statins use corrects the impact of direct acting antiviral agents on lipid profile in hepatitis C virus patients	Anna Mantovani	Received

THU-423	Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)	Yvonne Serfert	Received

SAT-423	The role of HBV genotypes in HBV relapse after cessation of entecavir or tenofovir in HBeAg-negative patients without cirrhosis	Chien-Hung Chen	Received

SAT-424	Impact of ESC technology on the hepatic safety profile of GalNAc-delivered, HBV-targeting RNAi therapeutics	Daniel Cloutier	Received

THU-424	The quetiapine question: management strategies for drug-drug interactions with antipsychotics and direct acting antivirals; a multicentre review	Katherine Davidson	Received

FRI-424	Medium-term outcomes of hepatitis C virus-infected patients with a sustained viral response according to albumin-bilirubin grade	Akihiro Tamori	Received

SAT-425	A once-per-week or every-two-week dosing regimen is more efficacious for the TIR7 agonist JNJ-64794964 (JNJ-4964) to induce an anti-hepatitis B virus (HBV) effect and HBV-specific immune responses in AAV-HBV mice	Florence Herschke	Received

THU-425	Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection	Lisette Krassenburg	Received

FRI-425	Identification of serum miRNAs whose expression were associated with and changed after HCV eradication	Atsumasa Komori	Received

FRI-426	Impact of genetic variants on liver disease regression in HCV patients with advanced chronic liver disease who achieved SVR to IFN-free therapies	Bernhard Scheiner	Received

SAT-426	In vitro and in vivo characterization of VIR-2218, an investigational RNAi therapeutic targeting hepatitis B virus	Florian Lempp	Received

SAT-427	Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF)	George Papatheodoridis	Received

THU-427	Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness	Candido Hernandez	Received

FRI-428	HIV/HCV co-infected subjects show better thrombocytopenia improvement after sustained virologic response achievement than HCV mono-infected cirrhotics. Data from the hepaiCONA and PITER cohorts.	Roberto Rossotti	Received

SAT-428	Early PEG-interferon-related ALT flares of high magnitude lead to HBsAg decline and loss. A study of 639 chronic hepatitis B patients	Hannah S.J. Choi	Received

THU-428	Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low-income refugees	Lorebzo Onorato	Received

THU-429	Elimination of hepatitis C in a remand prison using a rapid point of care driven test and treat pathway	Louise Davies	Received

SAT-429	Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study	Vithika Suri	Received

FRI-429	Long-term liver fibrosis and outcomes in HCV-infected solid organ transplant recipients after DASSs-induced viral eradication	Chiara Manuli	Received

THU-430	Dermatological manifestations in the era of new direct acting antivirals: a single-center experience	Mohamed Talkhan	Received

SAT-430	Residual low HDV viremia is associated with HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis D (delta): results from the HIDIT-II study	Heiner Wedemeyer	Received

FRI-430	Development of hepatocellular carcinoma by patients aged 75 years or over after HCV elimination by all-oral DAA therapy: results from a large-scale, multicenter cohort study	Eiichi Ogawa	Received

SAT-431	Combination drug interactions of hepatitis B virus (HBV) S-antigen transport - inhibiting oligonucleotide polymers in vitro	Hua Tan	Received

THU-431	Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction services in Kenya	Matthew Akiyama	Received

FRI-431	Deteriorated lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication	Chung-Feng Huang	Received

SAT-432	Bile acid derivatives inhibit hepatitis B virus infection in vitro and in vivo	Kiyoaki Ito	Received

THU-432	Real-life experience of direct acting antiviral treatment for chronic hepatitis C infection in adolescent patients in a low prevalence setting	Mary Flanagan	Received

FRI-432	Dynamic of cytokine profiles predicts risk of HCC among HCV patients with advanced fibrosis after successful antiviral therapy	Ming-Lung Yu	Received

SAT-433	Early on-treatment ALT normalization in patients with chronic hepatitis B is associated with lower risk of hepatocelluar carcinoma development	Jong Eun Yeon	Received

THU-433	Treatment of hepatitis C at the Stockholm needle syringe program - treatment success, reinfection rates and challenges for HCV elimination	Martin Kberg	Received

FRI-433	Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis	Giordano Sigon	Received

THU-434	Epidemiological and clinical analysis of foreign patients treated with direct antivirals for hepatitis C in a high immigration area	Matias Estevez	Received

SAT-434	Best in class hepatitis B virus anti-sense oligonucleotides: next generation bridged nucleic acid chemistries significantly improve the therapeutic index by reducing hepatotoxicity and increasing in vivo efficacy in a mouse model	Jin Hong	Received

THU-435	Drug-drug interactions (DDIs) with pangenotypic direct-acting antivirals (DAAs) in patients with hepatitis C; understanding the populations at risk and real-world care management	Michael Curry	Received

FRI-436	Role of pre- and post-treatment transient elastography measurements in predicting hepatocellular carcinoma (HCC) among hepatitis C patients treated with direct acting antivirals (DAAs)	Abdel Aziz Shaheen	Received

THU-436	Health-Related Quality of Life Among People Receiving Opioid Agonist Therapy and Treatment for Hepatitis C Virus Infection: Results From CO-STAR	Michael Winterrowd	Received

THU-437	Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment	James Wilton	Received

FRI-437	Non-invasive tests predict the risk of hepatocellular carcinoma in hepatitis C patients after sustained virological response: impact on HCC surveillance	Javier Ampuero	Received

SAT-438	Solving the cold chain problem - development of a heat-stable therapeutic vaccine to combat chronic hepatitis B	Julia Sacherl	Received

FRI-438	Reinfection with hepatitis C following cure: results from the TraP Hep C program in Iceland - a prospective nationwide, population-based study	Jon Johannesson	Received

THU-438	A combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects	Xiao-Jian Zhou	Received

THU-439	Frequency and characteristics of DAAs failure in hepatitis C therapy	Pablo Florez-Díez	Received

FRI-439	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma	Emilie Crouchet	Received

SAT-439	Multicistronic DNA-based therapeutic vaccine as a promising candidate to treat chronic hepatitis B virus (HBV) infection	Helene Kerth	Received

FRI-440	Simple blood test criteria for non-cirrhosis plus age and post-treatment AFP rule-out the risk of hepatocellular carcinoma development after SVR	Masayuki Kurosaki	Received

SAT-440	EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects	Kajal Larson	Received

THU-440	Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries	Jeff Lehman	Received

THU-441	Fast-track-consultation protocol: an interdisciplinary and useful tool for treating drug user hepatitis C infection in addiction out-patient units	Silvia Acosta-López	Received

FRI-441	Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir	Laura Telep	Received

FRI-442	The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated chronic hepatitis C viral infection: an interim analysis in the PITER cohort	Loreta A. Kondili	Received

THU-442	Achieving hepatitis C elimination in people who inject drugs - interim results of an innovative screen-and-treat program in Austria	Caroline Schmidbauer	Received

SAT-442	Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study	Vithika Suri	Received

SAT-443	Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir	Lucio Boglione	Received

THU-443	Directly observed therapy for hepatitis C with sofosbuvir/velpatasvir alongside opioid substitution as a tailored microelimination strategy in PWIDs with a high risk of non-adherence - real-world data from Vienna, Austria	Caroline Schmidbauer	Received

FRI-443	Clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus	Marco Di Petrillo	Received

THU-444	Externalized HCV linkage-to-care cascade in the biggest harm reduction center in Barcelona: approaching a high-risk PWID population	Sabela Lens	Received

FRI-444	Identification of circulating microRNAs predictive of HCC in DAA-cured HCV-related cirrhosis	Marie-Laure Plissonnier	Received

SAT-444	Low HBcrAg and HBsAg levels identify patients most likely to achieve sustained response after nucleos(t)ide analogue cessation: results from a global individual patient data meta-analysis (create study )	Milan Sonneveld	Received

SAT-445	Silencing HBV expression using LNA gapmers: preliminary data of a new promising strategy	Maria Francesca Cortese	Received

FRI-445	Impact on health perception, quality of life and labor productivity of antiviral treatment for hepatitis C in patients without significant fibrosis	Matias Estevez	Received

FRI-446	Sustained virologic response to direct-acting antivirals does affect the risk of portal vein thrombosis in patients with advanced chronic liver disease	Mattias Mandorfer	Received

THU-446	Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment	Igor Starinskij	Received

SAT-446	The composition of HBsAg during peginterferon-alfa2a treatment can predict treatment response in HBV/HDV-coinfection	Maria Pfefferkorn	Received

SAT-447	All-cause mortality and liver-related death following entecavir, tenofovir disoproxil fumarate or lamivudine therapy among treatment-naive chronic hepatitis B patients in British Columbia, Canada	Mawuena Binka	Received

FRI-447	The one-year outcome of hepatitis B virus in Taiwanese patients with chronic hepatitis B and C co-infection after direct-acting antivirals	Ming-Lun Yeh	Received

THU-447	Microelimination beyond prison walls: subjects sentenced to non-custodial sentences, screening and immediate assisted treatment with navigator figure and telemedicine	Susana Llerena	Received

THU-448	Efficacy of sofosbuvir/velpatasvir (s/v): impact of treatment adherence	Tianna Magel	Received

FRI-448	Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland	Madeleine Caven	Received

SAT-448	Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice	Michael Curry	Received

SAT-449	Structural requirements for S-antigen transport-inhibiting oligonucleotide polymer inhibition of hepatitis B surface antigen secretion	Megan Fitzgerald	Received

THU-449	Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis	Timothy Papaluca	Received

SAT-450	Low hepatitis B surface antigen at baseline and increased ALT levels during treatment predicts significant HBsAg decline in peginterferon alfa added to long-term nucleus(t)ice analogue. Results from two randomized controlled trials in 165 patients	Mina Farag	Received

FRI-450	Influence of DAA treatment in patients with HCV-cirrhosis and esophageal varices on liver transplant free survival and risk of developing hepatocellular carcinoma	Noelia Rodríguez Ferreiro	Received

SAT-451	Efficacy and safety of switching to tenofovir alafenamide for chronic hepatitis B patients with advanced fibrosis and partial virologic response to oral nucleos(t)ide analogues (ESTAB-AFPVR) - an interim report	Ming-Lun Yeh	Received

THU-451	HCV DAA treatment failure is associated to hepatocellular carcinioma presence	Ubaldo Visco-Comandini	Received

SAT-452	Efficacy and safety of GLS4/ritonavir combined with entecavir in HBeAg-positive patients with chronic hepatitis B: interim results from phase 2b, multi-center study	Mingyuan Zhang	Received

THU-452	Challenges in hepatitis C elimination despite highly effective antiviral agents - experience of a tertiary hepatology centre	Christian Urak	Received

FRI-452	Non-invasive tests of fibrosis and risk of liver-related complications: observations following successful sofosbuvir-based treatment in patients with HCV cirrhosis	Marianne Camargo	Received

SAT-453	Long-term efficacy of generic antiviral drugs (tenofovir and entecavir) in supression of viral replication in chronic hepatitis B	Marta Casado	Received

FRI-453	Hepatocellular carcinoma following direct acting antiviral therapy does not display an aggressive pattern: a prospective study	Reham Soliman	Received

FRI-454	Long-term evaluation of liver stiffness in HCV patients after sustained virological response to DAAs: predictive factors for disease improvement and hepatocellular carcinoma development	Riccardo Nevola	Received

FRI-455	Hepatitis C virus infection, endogenous retrotransposons activation and cancer risk	Ruchi Shukla	Received

THU-455	Hepatitis C positive organ transplantation to negative recipients at a multi-organ Canadian transplant centre: ready for prime time	Waleed Alghamdi	Received

SAT-455	ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B	Qingling Zhang	Received

SAT-456	Longer consolidation duration is required to reduce 1-year clinical relapse rate after stopping tenofovir in HBeAg negative CHB patients	Rachel Wen-Juei Jeng	Received

FRI-456	Post-treatment wisteria floribunda agglutinin-positive mac-2-binding protein is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication	Shunsuke Sato	Received

FRI-457	Erradication of HCV with direct-acting antivirals increased small LDL particle number in SVR48	Vanesa Bernal Monterde	Received

SAT-457	Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression	Rajender Reddy	Received

SAT-458	Immtav, a novel immunotherapy approach to eliminate hepatitis B virus	Ruth Martinez Hague	Received

THU-458	Neutrophil-lymphocyte ratio predicts the risk of developing hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B under antiviral therapy	Ke Shi	Received

FRI-458	Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance	Vincenza Calvaruso	Received

THU-459	Differentiation and management of hepatobiliary mucinous cystic neoplasms: a single-center experience for 10 years	Junhao Zheng	Received

SAT-459	HBV RNA decline without concomitant HBsAg decrease is associated with a low probability of sustained response and HBsAg loss	Sylvia Brakenhoff	Received

FRI-459	Partial restoration of brain structural and connectivity changes after HCV cure with direct acting antivirals (DAA)	Zoe Mariño	Received

THU-460	Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection	Hui Li	Received

SAT-460	HBV specific ImmTAV induce a broad immune response enabling the elimination of HBV positive cells	Joannah Fergusson	Received

SAT-461	Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials	Vithika Suri	Received

FRI-461	EIF4EBP3, methylated in gastric cancer, acts as a tumor suppressor restraining tumor proliferation and liver metastasis via targeting EIF4E/B-catentin axis	Zhongjie Lin	Received

THU-461	Serum and urine extracellular vesicles contain specific RNAs with diagnostic capacity for cholangiocarcinoma, being possibly involved in disease pathogenesis	Ainhoa Lapitz	Received

FRI-462	Molecular characterization of hepatocellular carcinoma in Mongolia delineates unique genomic features	Marc Puigvehí	Received

SAT-462	Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers	Sneha V. Gupta	Received

THU-462	Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC)	Ainhoa Lapitz	Received

SAT-463	Characterization of IL-21-expressing recombinant hepatitis B virus (HBV) as a therapeutic agent targeting persisting HBV infection	Jingwen Wu	Received

THU-463	Investigating the impact of extrahepatic metastasis in patients with HCC: does location matter?	Aline Maehringer-Kunz	Received

FRI-463	NK-cell dysfunction in hepatocellular carcinoma: modulatory approches for functional restoration	Alessandra Zecca	Received

FRI-464	Global characterisation of tumour infiltrate of intrahepatic cholangiocarcinoma by single cell sequencing	ana Lleo	Received

SAT-464	Optimising delivery of therapeutic hepatitis B vaccines to induce resident memory T cells in the liver	Sanjana Narayan	Received

THU-465	The PNPLA3 G-allele is common in patients with HCC but does not affect tumor characteristics and tumor biology	Benedikt Schaefer	Received

FRI-465	New prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma	Anne Olbrich	Received

THU-466	Long-term risk of HCC in HCC	Bonnie Bengtsson	Received

SAT-466	Functional cure based on pegylated interferon ? in long-term nucleoside analog suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest project in China), an interim report	Ze-Qian Wu	Received

SAT-467	Occurence of hepatocellular carcinoma in chronic hepatitis B patients undergoing entecavir or tenofovir treatment: a multicenter study in Taiwan	Yi-Hsiang Huang	Received

FRI-467	T cell exhaustion dynamics are linked to clinical outcomes in hepatocellular carcinoma	Maryam Treiber	Received

THU-467	Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma	Gian Paolo Caviglia	Received

SAT-468	Anti-HBS induction and HBsAg reduction by nasal administration of a therapeutic vaccine containing HBsAg and HBcAg (NASVAC) in patients with chronic HBV infection	Osamu Yoshida	Received

THU-468	Contrast-enhanced ultrasound using sonazoid in liver imaging reporting and data system category 3 and 4 observations on gadoxetate-enhanced magnetic resonance imaging	Yeun-Yoon Kim	Received

FRI-469	Dysregulation of aquaporin-1 in human CCA cells triggers epithelial-mesenchymal transition	CESAR GASPARI	Received

THU-469	Active chronic hepatitis B increases the risk of liver metastasis - a retrospective observational study of 7,187 consecutive newly diagnosed colorectal cancer	Yue Yang	Received

THU-470	Identification and etiology-dependent evaluation of diagnostic algorithms for early detection of hepatocellular carcinoma	Dave Morgenstern	Received

FRI-470	Diagnostic performance of PIVKA-II in patients with hepatocellular carcinoma	Claudio Galli	Received

FRI-471	TGF-beta-associated circular RNAs in cholangiocarcinoma: mechanisms and biomarkers	Corentin LOUIS	Received

THU-471	Optimisation and qualification of tumour mutational burden (TMB) by targeted next-generation sequencing (TNGS) as a clinically applicable biomarker in hepatocellular carcinoma (HCC)	David J. Pinato	Received

FRI-472	Tracking neutrophils within the hepatocellular carcinoma microenvironment - development of relevant orthotopic and ex-vivo 3D liver-HCC culture models	Daniel Geh	Received

THU-472	Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma	David J. Pinato	Received

FRI-473	Identification of PD-L1- expressing exosome-derived microRNAs in human hepatocellular carcinoma	Yu Rim Lee	Received

SAT-474	LXR agonism potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription	Zhongjie Lin	Received

THU-476	Circulating microRNA-21 and microRNA-122: prognosis prediction and correlation with HIF-1alpha in hepatocellular carcinoma patients treated with transarterial chemoembolization	Filippo Pelizzaro	Received

FRI-476	Identification of neoantigens as potential vaccines in hepatocellular carcinoma	David Reparaz	Received

THU-478	Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study	Federico Ravaioli	Received

FRI-478	Development of personalised human immunocompetent ex vivo models of primary and secondary liver cancers using precision cut tissue slice technology	Ewald Doornebal	Received

SAT-479	Transarterial radioembolization versus systemic treatment for the management of hepatocellular carcinoma with vascular invasion: analysis of the US national cancer database	Joseph Ahn	Received

FRI-479	Macrophage autophagy protects against hepatocellular carcinoma by modulation of the hepatic immune microenvironment	Fatima TEIXEIRA-CLERC	Received

THU-479	Prognostic and diagnostic role of angiogenesis biomarkers in hepatocellular carcinoma treated with chemoembolization	Giulia Peserico	Received

SAT-480	ALBI grade is a good predictive parameter for prognosis in advanced HCC patients with nivolumab therapy	Wei Teng	Received

THU-480	Risk of hepatocellular carcinoma in hepatitis D co-infected patients compared to hepatitis B mono-infected patients: a systematic review and meta-analysis	Habiba Kamal	Received

SAT-481	Early changes in circulating FGF19 and ANG-2 levels as a possible predictive biomarker for lenvatinib therapy in hepatocellular carcinoma	Makoto Chuma	Received

THU-481	The combination of EpCAM-positive circulating tumor cells and serum AFP/AFP-L3/DCP predicts outcome after curative resection of hepatocellular carcinoma	Johann von Felden	Received

SAT-482	The volume of enhancement of disease (VED) predicts the early response to treatment and overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib	Claudia Campani	Received

THU-482	Intratumoral EpCAM-positive cancer stem cell heterogeneity in patients with hepatocellular carcinoma and its impact on clinical outcome	Jenny Krause	Received

FRI-482	Comprehensive analysis of cancer-related genes and AAV/hepatitis B virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis B virus infection	Fukiko Kawai-Kitahata	Received

SAT-483	Alcoholic liver disease is associated with a poorer survival after radioembolisation for hepatocellular carcinoma	Clemens Schotten	Received

THU-483	Quantitative magnetic resonance imaging predicts individual future liver performance after liver reception for cancer	John Connell	Received

FRI-484	TIGIT and PD1 dual checkpoint blockade restores functionality of tumor-infiltrating T cells in hepatocellular carcinoma	Zhouhong Ge	Received

THU-484	Care pathway for patients with hepatocellular carcinoma in France in 2017: management overview, description of nurse coordinators role and its impact	Julie Devictor	Received

SAT-484	HBsAg relapse after living donor liver transplantation in hepatocelluler carcinoma patients with hepatitis D virus infection may result in hepatocellular carcinoma relapse	Adil Baskiran	Received

SAT-485	13C-methacetine breath test for the prediction of liver damage caused by transarterial chemoembolization in patients with hepatocellular carcinoma	Katarina Gluic	Received

FRI-485	Regulation of the biology of cholangiocarcinoma (CCA) cells by the extracellular-signal regulated kinase 5 (ERK5)	Giulia Lori	Received

THU-485	Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides	Julien Calderaro	Received

FRI-486	Fatty acids regulate the biology of cholangiocarcinoma cells	Giulia Lori	Received

THU-486	Deep learning for cost-effective accurate diagnosis of liver tumor based-on magnetic resonance imaging and clinical information: a retrospective study	Shihui Zhen	Received

SAT-486	Influence of acute kidney injury on the prognosis of patients receiving transarterial transembolisation for hepatocellular carcinoma: based on ICA-AKI criteria	Won Sohn	Received

THU-488	The risk of hepatocellular carcinoma recurrence following resection or ablation is dependent on underlying etiology	Laura Telep	Received

FRI-488	Modelling liver tumor organoids and cancer-associated fibroblasts interaction reveals the robust effects of stromal niche in cancer nurturing and treatment resistance	Jiaye Liu	Received

SAT-490	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in patients with advanced hepatocellular carcinoma	Johann von Felden	Received

THU-490	The protective role of urea-containing cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma	Young-Sun Lee	Received

FRI-490	ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and paracrine signaling between tumor cells and cancer-associated fibroblasts	Javier Vaquero	Received

THU-491	Applicability of the six and twelve model in patients with hepatocellular carcinoma treated with DEB-TACE	Maria Pipa Muñiz	Received

SAT-491	Diagnostic value of brush cytology alone and in combination with tumor marker in malignant biliary stricture	Jaseem Ansari	Received

THU-492	Application of acoustic radiation force impulse elastography in non-invasive diagnosis of focal nodular hyperplasia	Mariana Forlino	Received

FRI-493	Interplay of PNPLA and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C virus infected patients	Carla De Benedittis	Received

THU-494	Incidence of hepatotoxicity in patients with hepatocellular carcinoma on treatment with immune checkpoint inhibitors: impact on outcomes and tissue biomarker analysis	Nicola Personeni	Received

FRI-494	Alisporivir, a cyclophilin inhibitor, reduces fibrosis and tumor burden derived from non-alcoholic steatohepatitis in a mouse model	Joseph Kuo	Received

SAT-495	Safety and efficacy of lenvatinib in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice	Katsuaki Ogushi	Received

SAT-496	Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization before designing clinical trials comparing transarterial chemoembolization and immune checkpoint inhibitor-based therapies	Keisuke Koroki	Received

FRI-496	SPARC negatively correlates with prognosis after transarterial chemoembolization and facilitates growth and metastasis of hepatocellular carcinoma via ERK/MMP signaling pathways	Yao Liu	Received

THU-496	Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2	Sukanya Chaudhury	Received

FRI-497	Patient-derived ECM-scaffolds of colorectal cancer and liver metastases as organotypic 3D model of liver metastatic colonization	Luca Urbani	Received

SAT-497	High rate of hepatitis B virus S-integrated human extra spindle pole bodies like 1 fusion gene is detected in hepatitis B virus-related liver cancer patients: a Chinese case-control study	Rongming Wang	Received

FRI-498	Interplay between O-GlcNAc transferase and enhancer of zeste homolog 2 in hepatocellular carcinoma	Margot Thirion	Received

FRI-499	The metabolic plasticity of neoplastic cholangiocytes: perspective for target therapy in intrahepatic cholangiocarcinoma.	michela anna polidoro	Received

SAT-499	Chlorogenic acid decreases malignant characteristics of hepatocellular carcinoma cells by inhibiting DNMT1 expression	Yao Liu	Received

FRI-500	Mitochondrial oxidative metabolism contributes to maintain a cancer stem cell phenotype in cholangiocarcinoma	chiara raggi	Received

SAT-500	Protective role of aspirin chronic assumption in patients treated with sorafenib for hepatocellular carcinoma	Luca Ielasi	Received

THU-501	Refining the immune class of hepatocellular carcinoma	Roser Pinyol	Received

FRI-502	NEDD8 specific protease 1 (NEDP1) as a tumor suppressor in hepatocellular carcinoma	Marina Serrano-Macia	Received

SAT-502	In vivo performance of PEG-coated gold nanoparticles mediated ultrasound guided radiofrequency ablation: a pilot study in swine	Tudor Mocan	Received

FRI-503	Piddosome-controlled liver ploidy is predictive for HCC outcome	Nataliya Rohr-Udilova	Received

THU-503	Cholangiocarcinoma miscoding in hepatobiliary centres	Shaun Selvadurai	Received

SAT-503	The six-and-twelve score in a prospective cohort of patients with hepatocellular carcinoma treated with trans-arterial chemoembolization following a fixed schedule	Marco Sanduzzi Zamparelli	Received

THU-504	Non-alcoholic steatohepatitis is a risk factor for intrahepatic cholangiocarcinoma and affects its long-time outcome: results from a multicenter international case-control study	Stefania De Lorenzo	Received

SAT-504	Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib monotherapy in advanced hepatocellular carcinoma: a systemic review and meta-analysis	Zhiyuan Yao	Received

THU-505	Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic hepatitis B and C patients	Stijn Van Hees	Received

SAT-505	Dexamethasone prophylaxis of postembolization syndrome after transcatheter arterial chemoembolization: a randomized, double-blind, placebo-controlled study	Panot Sainamthip	Received

THU-506	TERT mutated circulating tumor DNA is a useful biomarker and predicts prognosis in Danish HCC patients	Stine Karlsen Oversoe	Received

FRI-507	A pro-inflammatory variant in the TLR5 gene is associated with hepatocellular carcinoma in patients with cirrhosis due to steatohepatitis.	Philipp Lutz	Received

THU-508	Cholangiocarcinoma in England - a national study examining changes in incidence, diagnostic routes and overall survival	Shahid Khan	Received

FRI-509	Hepatitis B virus surface antigen inactivates the hippo pathway and thereby increases the hepatic expression of oncogene BMI1	Ruth Broering	Received

THU-509	Reduced incidence of hepatobiliary cancers in helicobacter pylori infected persons in a population-based cohort study	Linda Skibsted Kornerup	Received

THU-510	Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model	Vito Sansone	Received

FRI-510	Natural killer cells target XPO1: a therapeutic opportunity for HCC	Salim Khakoo	Received

SAT-511	Prognostic value of alpha-fetoprotein in patients achieving complete response to transarterial chemoembolisation for hepatocellular carcinoma	Jae Seung Lee	Received

FRI-511	Myeloid IRE1a deletion alters hepatic macrophage phenotype and attenuates experimental non-alcoholic steatohepatitis-related hepatocellular carcinoma	Sanne Van Campenhout	Received

SAT-513	Updated data from an ongoing study with ADP-A2AFP spear T-cells	Marianne Heery	Received

FRI-513	Exposing the regulation of MDM2 expression by ADAR-mediated A-to-I editing in human hepatocellular carcinoma: application of a large-scale on-step predicting platform in oncology research	Guangqi Song	Received

SAT-514	A nationwide multicenter study of Japanese patients with unresectable hepatocellular carcinoma treated with regorafenib in real-world practice	Kaoru Tsuchiya	Received

FRI-515	BAP1 loss in hepatocellular carcinoma is associated to PKA activation and fibrolamellar features	Theo Hirsch	Received

SAT-515	Antiplatelet therapy improves the prognosis of patients with hepatocellular carcinoma	TSUGURU HAYASHI	Received

THU-515	Chronological improvement in long-term outcomes of surgical resection for patients with hepatocellular carcinoma: two large-volume center studies	Yun Bin Lee	Received

SAT-516	No risk of hepatitis B reactivation in hepatocellular carcinoma patients with HBV-DNA 100 iu/ml undergoing immune checkpoint inhibitor immunotherapy by pre-emptive strategy	Pei-Chang Lee	Received

SAT-517	Effect of antibiotics, proton pump inhibitors and steroids on survival and response to immune-checkpoint inhibitors in patients with hepatocellular carcinoma	Pei-Chang Lee	Received

THU-517	Estimation of hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance	Yewan Park	Received

THU-518	Indeterminate nodules in hepatocellular carcinoma surveillance: an analysis of the frequency, outcomes and costs	Yu Meng Li	Received

THU-519	Serum creatinine / cystatin C ratio has a potential as a useful surrogate marker for evaluation of muscle mass volume in patients with hepatocellular carcinoma	Kazufumi Kobayashi	Received

SAT-519	Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure	Yun Bin Lee	Received

About us

FAQs

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 27/08/2020 TO 27/08/2021

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.ILC2020.2020



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access